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ABSTRACT 
Customized patient therapy has been a major research focus in recent years. There 
are two research fields that have made a significant contribution to realizing 
individualized-based treatment: targeted drug delivery and three-dimensional (3D) 
printing technology. With benefit from the advances in nanotechnology and biomaterial 
science, various drug delivery systems have been established to provide precise control of 
therapeutic agents release in time and space. The emergence of three-dimensional (3D) 
printing technology enables the fabrication of complicated structures that effectively 
mimic native tissues and makes it possible to print patient-specific implants. My 
dissertation research used a clay nanoparticle, halloysite, to develop a drug delivery 
system and 3D scaffold which may contribute to individualized-based treatment. 
Halloysite nanotubes (HNTs) are naturally occurring tubular nanoparticles with a 
hollow lumen. They possess a high aspect ratio, thermal stability, and unique oppositely 
charged inner and outer surfaces. These inherent features enable them to be used as a 
bulk filler to improve the performance characteristics of many polymers. Besides, HNTs 
are biocompatible and have a demonstrated capacity to delivery growth factors, RNA, 
DNA and other chemical substances; therefore, HNTs have received extensive attention 
in the development of drug delivery systems. In this dissertation, HNTs were applied in 
the development of medical devices for bone disease remediation, tissue regeneration, 
and restoration of bone function.     
iv 
Osteomyelitis is a bone infection and mainly caused by Staphylococcus aureus (S. 
aureus). Gentamicin is the antibiotic commonly used to against gram- negative and 
positive bacteria, which includes S. aureus. When gentamicin was loaded into HNTs and 
incorporated with chitosan, the hybrid chitosan/HNTs hydrogels provided a sustained 
drug release and successfully inhibited the growth of S. aureus. Simultaneously, the 
addition of HNTs improved chitosan mechanical properties. 
Osteosarcoma is the most common cancer tumor occurring in bone tissue. 
Through surface modification, HNTs were conjugated with folic acid and fluorochrome 
(FITC). The bi-functionalized HNTs (bHNTs) were then doped with anticancer drugs, 
methotrexate (MTX). MTX-doped bHNTs showed a high drug loading efficiency and 
selectively targeted cancer cells. MTX-loaded bHNTs efficiently inhibited osteosarcoma 
proliferation without harm to normal type cells (pre-osteoblasts). 
Osteoporosis is the most common bone disease as the bone formation fails to keep 
up with the bone resorption rate. Bone fractures happen as a result of long-term bone 
defection. Three dimensional printed scaffolds that support bone regeneration could be a 
viable alternative to bone grafting, which is limited by insufficient supplies and issued 
with infection. Metal-doped HNTs were combined with PLA and printed with a specific 
pore size and porosity design. After surface modification, 3D printed HNTs/PLA 
scaffolds encouraged cell adhesion and osteogenic differentiation. Furthermore, surface 
coating of gentamicin had a long stock life to inhibit bacterial growth and promoted 
osteogenesis. 
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CHAPTER 1 
 
INTRODUCTION 
 
1.1 Halloysite Nanotubes 
1.1.1 Halloysite Nanotube Structure  
Halloysite was first discovered in Belgium and received substantial research 
interests as a mineral material in the 1940s 1. Since 2012, it has gained increased attention 
due to its nano size hollow tubular structure. Halloysite is aluminosilicate clay 
(Al2Si2O5(OH)4nH2O), it naturally folded to form nanotubes. Halloysite nanotubes 
(HNTs) are multi walls consisted by octahedrally coordinated Al3+ and tetrahedrally 
coordinated Si4+ in a 1:1 stoichiometric ratio 2. The particle size of HNTs is 0.5-2 µm in 
length with an inner diameter of 10-30nm and external diameter of 50-70nm 2. As Figure 
1-1 shows, aluminons are folded inside towards the lumen, while siloxanes are exposed 
on the outer surface; therefore, the lumen of HNTs are positively charged, while the 
external surface of HNTs are negatively charged. 
2 
 
Figure 1-1: Halloysite nanotubes structure. The tubular structure formed by the 
conjunction of silicone dioxide and aluminum oxide layers. 
Due to its high aspect ratio, hollow tubular structure, and different charges of 
inner and outer surface, HNTs have various applications as ceramic raw materials 3, 
nanocontainers for active compounds, catalysts, adsorbents 4–8, and polymer fillers 9–12. It 
has been largely reported that HNTs is biocompatible, thus its application has been 
expanded to tissue engineering, drug delivery, and biomaterial compositions 1,13–15. 
1.1.2 Halloysite Nanotubes Application ¾ Drug Delivery 
HNTs is thermal stable, their hollow tube microstructure is a good candidate for 
sensitive or toxic drugs carrier. Drugs can be loaded into the lumen with a circulating 
process of vacuum and sonication. Drugs encapsulated in HNTs could be continually 
released for 30-100 times longer than applying drugs directly into surrounding solutions 
1. Furthermore, with the modification of aminopropyltriethoxysilane (APTES), HNTs can 
conjugate with other chemicals, such as folic acid and magnetite nanoparticles and 
3 
release drug at specific pH environment 13. The inner surface can be modified by 
phosphonic acid, which targets alumina, to enlarge the capability of encapsulating neutral 
and hydrophobic guest molecules. Simultaneously, the out surface can be modified to be 
solid polar with the treatment of salinizing agents, which results in a stable dispersion of 
HNTs in water 14.  
1.1.3 Halloysite Nanotubes Application ¾ Bulk Filler 
HNTs are excellent nanofillers to reinforce variety of materials. Their surface 
stiffness, thermal stability, strength and modulus can be improved due to the nanoscale, 
high strength and high aspect ratio of HNTs 1. In addition, HNTs are eco-friendly and 
low-cost material and have abundant storage in natural.  
1.1.4 Halloysite Nanotubes Application ¾ Tissue Engineering 
Due to the enhancement of mechanical properties, HNTs have been employed in 
tissue engineering to cooperated with traditional materials for a better performance. 
Porous chitosan-gelatin-agarose hydrogels combined with HNTs have been demonstrated 
to be biocompatible both in vitro and in vivo. In addition, it promoted the formation of 
novel blood vessels and can be absorbed in 6 weeks in vivo 15. 
1.1.5 Halloysite Nanotubes Application in My Study 
In my projects, HNTs were employed as drug carriers and reinforcement 
additions. Through incorporating with other polymers or working as its own, we assessed 
the influence of HNTs in the application to address three bone diseases: osteomyelitis, 
osteosarcoma, and osteoporosis.  
4 
1.2 Bone Diseases 
The control mechanisms for skeletal systems can be disrupted in many ways and 
lead to a number of clinically important bone diseases.  
1.2.1 Osteomyelitis 
Osteomyelitis is a bone infection mostly caused by bacteria or rarely by fungi. It 
may be caused by open wound contamination, intravenous drug abuse, diabetes, 
prosthetic implants, surgery, hemodialysis, and removal of the spleen 16. Humans of any 
age are susceptible to osteomyelitis. The epiphysis (growth plate) of bones of the legs and 
arms are the most frequently affected bone sites in children and teens. While, the 
vertebrae of the spine or the pelvis are often affected in adults 17.  
In children, osteomyelitis is generally acute, which develops over several days or 
weeks. Osteomyelitis in adults can be either acute or chronic. Chronic osteomyelitis 
usually occurs if the acute osteomyelitis has not been completely remediated, and it can 
last as long as several months or even years 17. Patients with osteomyelitis suffer from 
fever, fatigue, redness and tenderness, swelling, and pain associated with the affected 
sites. The persistence of microorganisms at diseased bones causes bone destruction and 
necrosis, which often results to amputation 16. 
1.2.2 Osteosarcoma 
 Osteosarcoma is the most common cancerous tumor in the bone. In general, 80% 
to 90% of osteosarcoma arises in the long bones such as the femur, tibia, and humerus; 
while less than 1% are found in hands and feet bones; more rarely, it may occur in the 
soft tissue 18. Teenagers and young adults are more frequently affected by osteosarcoma 
compared to children and adolescents. The etiology of osteosarcoma has not been 
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completely studied, the only verified environmental agent that causes osteosarcoma is 
ionizing radiation 19. The presence of retinoblastoma may also increase the risk of 
osteosarcoma in the patients and their descendants 20. In addition, a constitutional 
germline mutation of p53 was found in 3% to 4% of children who suffered with 
osteosarcoma 21. Most patients with osteosarcoma suffered with pain. Due to the deep-
seated tumor, localized swelling may not be apparent, but continuously bone destruction 
are happening, which results in bone fracture. Pediatric patients are more vulnerable with 
a sudden bone fracture than adult patient 18. 
1.2.3 Osteoporosis 
Osteoporosis is the most common bone disease and is characterized by bone loss, 
because bone formation fails to keep up with the rate of bone resorption. The 
deterioration of bone structure and long-term bone mass loss increase the risk of bone 
fracture. Osteoporosis can develop in a number of ways including aging, race, lifestyle 
and medical condition. Age-related osteoporosis is the most common form of this disease 
and is referred as “primary osteoporosis”. Osteoporosis that is caused by specific diseases 
or medications is classified as “secondary osteoporosis” 22. Bone fractures in the spine, 
wrist, and hip are usually associated with osteoporosis. Severe bone fracture introduces 
chronic pains, and patients may be disabled and require long-term hospitalization. 
1.3 Disease Treatments and Bone Regeneration 
1.3.1 Current Treatments for Osteomyelitis 
Osteomyelitis is inflammation of the bone and marrow that is caused by bacteria 
or fungus infection. Staphylococcus aureus (S. aureus) is the most commonly involved 
microorganism in all forms of osteomyelitis 23. Clinically, a sterilized environment, 
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standard preoperative sterilization, and prophylactic antibiotic treatment have 
successfully decreased the infection rate of implanted prostheses to 0.5-2.0% 17. 
However, insufficient osseointegration frequently happens after orthopedic implant 
surgeries. The appearance of interval between native tissue and prosthesis gives a chance 
for microorganism invasion. Once they form biofilm, a revision surgery is necessary to 
remove the foreign implant. The revision operation would bring more pain and high 
medical cost to patients and decrease their life quality. 
1.3.2 Current Treatments for Osteosarcoma 
In the past, patients with osteosarcoma were often treated by amputation, which 
created significant pain and only had a cure rate of less than 10% 18. After decades of 
development, advanced diagnostic methods provide more information to evaluate the 
extent of tumors and decide the treatment strategy. Localized osteosarcoma, where cancer 
cells have not spread to other tissue beside the initial site, is currently treated by surgery 
and combined with pre- and postoperative chemotherapy 18. However, the rate of local 
recurrence is as high as 25%  and it will be higher if adequate surgical margins are not 
achieved 24. When cancer cells spreading to other tissue (metastatic osteosarcoma) such 
as the lung and forming pulmonary nodules, the affected tissues need to be excised 
together with the primary tumor to prevent recurrence 18.  
1.3.3 Current Treatments for Osteoporosis 
Osteoporosis is an accumulation process of bone mass loss with gradual bone 
deterioration. The imbalance between bone resorption and bone formation leads to a 
thinner cortical bone and damages to the trabecular bone structure. Osteoporosis is 
asymptomatic unless bone fractures happened. Osteoporosis can be prevented or delayed 
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by a healthy lifestyle that includes a nutritious diet, adequate calcium and vitamin D 
intake, and regular physical exercise 22. Prescription medications can slow bone loss 
(bisphosphonates, raloifene, alendronate, raloxifene) or promote bone formation 
(teriparatide), but these drugs have associated side effects 25. 
1.3.4 Disadvantages of Current Bone Disease Treatments 
Other than removing the infected tissues by surgery and giving a systemic drug 
treatment when post-surgical infection arising, there is no efficient strategy to eliminate 
bacterial contamination that originates from implants and give antibiotics at the surgical 
site. Our first study focused on the development of a hydrogel drug delivery system that 
could address this problem. The final product of hydrogels could also be utilized for the 
surface coating of implants and provide a sustained and local drug release, which would 
dramatically decrease the risk of bacterial infection.  
A similar problem exists in the treatments for osteosarcoma. Surgery is the 
primary approach to excise tumors and continuing with low efficiency and painful 
chemotherapy. Conventional cancer drug administration goes through blood system or 
gastrointestinal system. In other words, drugs travel throughout the body before they 
attack cancer cells at tumor site. Usually higher dosage is required to reach tumor region. 
Consequently, healthy tissues are exposed to highly toxic pharmaceutical agents that 
disrupt the regular physiological activities and result in various side effects, such as 
fatigue, hair loss, anemia, infection, easy bruising and bleeding, numbness, tingling, pain 
and so on. Our second study of cancer target therapy is a promising solution to address 
this pain point. HNTs will be modified to selectively bind cancer cells and bring pre-
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loaded toxic drugs to the targeted cells. This method protects healthy cells from the 
harmful effects of the toxic drugs. 
Osteoporosis is not as dangerous as osteomyelitis and osteosarcoma until severe 
fractures occur. Bone grating is one of the most commonly used surgical methods to 
provide rigid support for fractured bones. It also can be used as joint augmentation or 
replacement for pain relief and function improvement 26. Bone grating may be also 
applied in treatment of osteomyelitis and osteosarcoma as the replacement of the excised 
bone portion. Due to the aging of populations and trauma caused by accident or exercise, 
over two million patients are suffered from bone injuries annually worldwide and await a 
bone graft for defect repair 27. Currently, in clinically available grafts, autografts are 
considered the gold standard because of their excellent properties in osteo-conduction, 
osteo-induction, and osteogenesis 28. However, concerns of limited supply and the 
attendant risks of donor site morbidity are still maintained 29. Allografts are another group 
of candidates for orthopedic implants. Nearly one third of all bone grafts used in North 
America are allografts 30. They are primarily osteoconductive but with less osteo-
inductivity, which increases the risk of nonunion and infection 31,32. Our third study of 3D 
bioprinting scaffold has great potential to change the source of bone grafts from 
autografts and allografts to variable biomaterials. Abundant resources of biomaterials 
enable 3D printed implants to be freely from supply limitation, even better, it provides 
customized printing based on individual requirement. 
1.4 Objectives 
My dissertation research has a diverse range of objectives with a unified goal of 
exploring the application of halloysite nanotubes in bone disease treatment. 
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• Objective 1: Develop a drug delivery system using chitosan/halloysite hybrid 
materials to prevent bacterial growth, which can be applied in implant coating.  
• Objective 2: Modify halloysite nanotubes to target osteosarcoma and reduce 
cancer cell growth.  
• Objective 3: Dope halloysite with metal nanoparticles and combine them with 
PLA to build a 3D scaffold for bone regeneration.  
1.5 Organization of Dissertation 
This dissertation is composed of five chapters. Chapter one is a brief introduction 
to the clay mineral, halloysite, three bone diseases and the status of current clinical 
treatments. Chapter two focused on enhancing chitosan mechanical properties with 
HNTs. The final hybrid hydrogels were used as a drug delivery system to inhibit bacterial 
growth. Chapter three focused on halloysite surface modification. The modified 
halloysite nanotubes successfully delivered anticancer drugs to cancer cells without harm 
of healthy cells. Chapter four focused on the 3D printing of composed PLA/HNTs. The 
addition of HNTs improved bone regeneration in three-dimensional cell culture. Chapter 
five discussed the potential applications of HNTs in medical devices for clinical 
treatment of bone disease and proposed future works.
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CHAPTER 2 
THE EFFECT OF HALLOYSITE ADDITION ON THE MATERIAL 
PROPERTIES OF CHITOSAN-HALLOYSITE HYDROGEL 
COMPOSITES  
The sections of this chapter have been published in: Luo and Mills, “The Effect of 
Halloysite Addition on the Material Properties of Chitosan–Halloysite Hydrogel 
Composites,” Gels, vol. 5, no. 3, p. 40, 2019. 
2.1 Introduction 
Oral ingestion and intravascular injection of antibiotics have a lengthy application 
history and are primarily used in the control of post-surgical infection. However, there is 
a high risk of negative side effects 33,34. These side effects are principally due to systemic 
administration through the blood vascular system, which is not directly to the target tissue 
35. In many cases, frequent administration of antibiotics is required to achieve the dosage 
levels needed to eliminate the infection, and this regimen has the potential to severely 
impact unaffected tissues resulting in additional medical issues for the patient, such as 
gastric, hematological, neurological, dermatological, allergic and other disorders 35. An 
implantable drug delivery system that can provide a defined drug load directly to the 
affected tissue is one strategy to resolve this problem. Key design considerations in 
building such a drug delivery system include biocompatibility, biodegradability, 
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mechanical stability, and the ability to provide sustained drug release. In this study, 
chitosan and halloysite were used to construct and test composite hydrogels that differed 
in percent concentration of these materials.  
Chitosan is a naturally derived hydrogel, usually produced by alkaline 
deacetylation and is biodegraded by human enzymes 36. Chitosan has been proven to be 
non-toxic, possesses a lack of immunogenicity, possesses the ability to sequester 
bioactive factors, and has the capability of assembling a tissue-specific extracellular 
matrix (ECM) 36–38. It also exhibits some antibacterial properties 39. This antimicrobial 
ability makes chitosan a suitable candidate for implant coatings, wound dressing, and 
drug delivery applications, but chitosan has a major flaw which is its inherent mechanical 
weakness 40–42. Many approaches, such as the addition of various polymers 43,44, carbon 
nanotubes 45,46, or clay nanoparticles 47,48, have been studied as a means to improve 
chitosan’s mechanical properties, and these additives increased the roughness of the 
scaffold which enhanced cell attachment, proliferation and differentiation 49–51. 
Halloysite nanotubes (HNTs) are naturally occurring nanotubes composed of 
silica and alumina 52, and exhibits a high degree of cytocompatibility hemocompatibility, 
and biocompatibility 53–55. They are 1D nanomaterials with a unique hollow tubular 
morphology that has an external diameter of 50-200nm, luminal diameter of 5-30 nm and 
a length of 0.5-2 μm 52. The electrokinetic behavior of HNT at pH 7 is defined by the 
negative surface potential of SiO2, with a small contribution from the positively-charged 
Al2O3 inner surface 56–58. As a polymer filler, HNTs have been shown to significantly 
improve the material properties of polymers and resins such as alginate 51, calcium 
phosphate cement 59, epoxy 12, nylon 11, poly(methyl methacrylate) 10, and rubber 60. The 
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unique hollow tubular structure enables HNTs to be used as drug carriers. The HNT 
lumen can serve as a reservoir for the loading and releasing of a diverse set of 
biologically active molecules, including small molecules, enzymes, nucleic acids, and 
proteins 4,6–8,61. Moreover, the loading capacity of HNTs can be further enlarged by 
chemical etching, thus increasing its cargo-carrying capacity 3.  
Chitosan (CS) combined with different types of nanoparticles have been 
extensively studied 62. Recent studies have shown that these nanocomposites are 
biocompatible, antimicrobial, and mucoadhesive and can be fabricated into various forms 
including coatings 63, films 64, hydrogels 51, and membranes 65. Furthermore, CS, with the 
addition of HNTs, has also been shown to significantly increase strength, tensile 
modulus, hardness, and toughness 49,66. However, these studies only reported on the 
effects that HNT addition had on polymer mechanical properties, however, the influence 
of chitosan and HNT concentration and the corresponding impact of different percent 
combination of these materials on the mechanical properties and cellular behaviors has 
yet to be established. 
In this study, chitosan was chosen to be cell growth scaffold due to its 
polycationic property and antibiotic potential 39,42. The drug-carrying capacity of HNTs 
was employed as additives to improve chitosan hydrogel mechanical properties. The 
resultant changes in hydrogel surface structure, tensile strength, stiffness, and 
degradability were studied. Gentamicin was selected as a model drug to assess drug 
release in CS/HNTs hydrogels of different compositions. Escherichia coli (E. coli) and 
Staphylococcus aureus (S. aureus) were used as a means for testing the bacterial growth 
inhibition capacity of the different hydrogels and in estimating drug efficacy. Pre-
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osteoblasts (MC3T3) were selected to study the potential cytotoxicity of CS/HNTs 
nanocomposites. 
2.2 Materials and Methods 
2.2.1 Drug Loading 
For drug loading, gentamicin sulfate (GS, Sigma Aldrich, St. Louis, MO, USA) 
was vacuum loaded into HNTs. HNTs (250 mg/ml.) were mixed with a 2 ml GS solution 
(250 mg/ml). The mixed suspension was placed in a vacuum and the suspension was 
vacuumed overnight. The gentamicin contained in the supernatant was measured to 
determine the drug loading efficiency.  
 Drug	loading	efficiency = gentamicin	in	supernatanttotal	amount	of	gentamicin	  Equation 2-1 
2.2.2 HNTs-Chitosan Hydrogel Construct 
Low molecular weight chitosan (Sigma Aldrich) was dissolved in 4% critic acid 
solution (Fisher Scientific, Houston, TX, USA) to form three chitosan concentrations: a 
3%, 4% and 5% w/v solution. Different concentrations of chitosan were combined with 
HNTs, with the concentration of HNTs ranging from 1% to 5%. Hydrogels were formed 
by crosslinking the mixture solution with 10% tripolyphosphate (TPP) (Sigma Aldrich).  
2.2.3 Scanning Electron Microscopy (SEM) Study 
The HNTs-chitosan mixture and pure chitosan solution (200 μL) were dropped 
into a 10% TPP solution to produce similar sized droplets. After 10 minutes, the beads 
had formed. They were then frozen at −20 °C for 24 hours and then lyophilized. The 
structures of hydrogel beads were studied using SEM (AMRAY SEM, Model: 1830, 
SEMTech Solutions, North Billerica, MA, USA).  
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2.2.4 Degradation Analysis 
0.25 ml hydrogels were cross-linked into micro-beads and incubated in PBS at 37 
°C for 24 hours first. Their initial weights were measured Wd1 after beads air-dried for 30 
minutes on filter paper. Then, the hydrogels were divided in two groups, one group was 
incubated in PBS, another group was incubated in 1 mg/ml lysozyme/PBS solution at 37 
°C. Their weights were measured every 2 to 3 days and recorded as Wdx. This study was 
continued for 14 days. The remained weight ratio for each sample was calculated as:  
 Weight	ratio = Wdx/Wd1 Equation 2-2 
2.2.5 Tensile Properties 
The chitosan-HNTs mixture and pure chitosan solution were poured into the same 
size mold, after they had totally dried, a 10% TPP solution was added for cross-linking 
chitosan. The crosslinked hydrogels washed with DI water for 3 times, then put on filet 
paper for air-drying. The prepared films were cut into similar sizes (10 mm × 20 mm), 
and the average thickness was 0.02 mm. The tensile strength (σ) and elongation (ε) of 
hydrogels was measured by CellScale Unit with 200 N load cell at a speed of 10mm/min. 
Young’s modulus (E) was calculated based on the equation of E= σ / ε. At lease 3 tests 
for each composite.  
2.2.6 Drug Release Study 
10 mg of drug loaded HNTs were mixed with 0.5 ml chitosan solution and cross-
linked with 10% TPP solution for 30 minutes. The samples were then rinsed with DI 
water 3 times to get rid of excess TPP solution. Then drug loaded hydrogel samples were 
incubated in 2 ml PBS at 37 °C to enable drug released from hydrogel to PBS. With 
designed incubation time, 2 ml PBS was collected and filled with fresh PBS. To measure 
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drug concentration, gentamicin containing PBS were combined with o-ophthalaldehyde 
(OPTA) solution and 50% isopropyl at a ratio of 1:1:1 by volume, the absorbance values 
were measured at 340 nm wavelength. A group of gentamicin solution with known 
concentration was used to establish standard calibration curve.  
2.2.7 Swelling Ratio 
Hydrogel beads composed of pure chitosan and chitosan/HNTs composites were 
prepared as above. Each hydrogel bead was incubated in 200 µL phosphate buffered 
saline (PBS) at 37 °C for 5 days. At day 1, 3, and 5, the swelling ratio of chitosan and 
chitosan/HNTs hydrogel composites were determined by the following equations, where, 
Ws represents the weight of swollen hydrogel after incubation in PBS, and Wd represents 
the weight of dried hydrogel after swelling.  
 Swelling	ratio = (𝑊𝑠 −𝑊𝑑)/𝑊𝑑 Equation 2-3 
 
2.2.8 Bacterial Inhibition Growth Test 
Cross-linked hydrogel beads, consisting of CS/HNTs and drug-loaded CS/HNTs, 
were placed in 1ml Escherichia coli (E. coli) and Staphylococcus aureus (S. aureus) 
suspension and incubated with nutrient broth (NB) and Mueller Hinton broth respectively 
at 37 °C for 24 hours. Pure bacteria suspension without any treatment was set as control, 
and pure broth was the blank. The absorbance value of samples were measured at 
wavelength of 630nm at time point of 0, 3, 16, and 24 hours. Each sample has three 
replicates. 
2.2.9 Live/Dead Cytotoxicity Assay 
48 well plates were pre-coated with CS or CS/HNTs hydrogel films on which 
MC3T3 cells (ATCC) were seeded at a density of 1 × 105/ml. Culture wells without any 
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film coating were used as controls. All cultures were then incubated at 37°C with 5% 
CO2 for 24 h. The Live/Dead assay (Life Technologies, Carlsbad, CA, USA) was applied 
according to manufacturer’s directions to assess any potential for cytotoxicity.  
2.2.10 Statistical Analysis 
Statistical analysis was conducted by using one-way ANOVA or Student’s t-test. 
All of the quantitative experiments were performed in triplicate or repeated three times. 
Data were expressed as “mean ± standard error”. Significance between experimental 
groups and/or controls was determined by one-way analysis of variance. A p-value less 
than 0.05 was considered statistically significant.  
2.3 Results 
2.3.1 SEM Studies 
Chitosan (CS) and chitosan/HNTs (CS/HNTs) hydrogels were dropped into 10% 
tripolyphosphate (TPP) solution. The ionic cross-linking happened between the NH3+ site 
of chitosan and OH- site on TPP. After 10 minutes of cross-linking process, spherical 
hydrogel beads were formed with an average diameter of 3.38 ± 0.28mm. For SEM 
analysis of surface and structural features of the hydrogel beads, beads were pretreated by 
lyophilization. The pressure changes in the vacuum chamber during lyophilization caused 
some hydrogel bead formulations to collapse and lose their spherical shape. A low 
concentration of chitosan (3% CS, Figure 2-1 A) was barely able to preserve its original 
spherical shape as the hydrogel walls collapsed. However, as the chitosan concentration 
increased, the hydrogel beads structure provided some resistance to deformation and 
collapse of the hydrogel wall structure (Figure 2-1 C and E). In contrast, the increased 
addition of HNTs may have enabled the CS/HNT hydrogels to resist deformation and 
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preserve a more rounded microbead shape. HNTs may have interacted with chitosan to 
form stronger walls and provide more support to the hydrogel matrix. Also, increased 
HNTs produced a rougher surface (compare Figure 2-1 D and F).  
 
Figure 2-1: SEM images of pure chitosan hydrogel beads with increased chitosan 
concentration (A, C, E) and chitosan/ Halloysite nanotubes (HNTs) wt./wt. 
composites (B, D, F). (A) 3% chitosan (CS), (B) 3% CS/2% HNTs, (C) 4% CS, (D) 
4% CS/2% HNTs, (E) 5% CS, (F) 5% CS/ 2% HNTs. 
2.3.2 Degradation 
CS and CS/HNTs hydrogel beads did not exhibit any weight loss when incubated 
in PBS without lysozyme (data not shown). When the hydrogel beads were incubated 
with lysozyme, they degraded gradually as expected, and their weight ratio decreased, as 
shown in Figure 2. Among the pure CS group (Figure 2-2 A), 3% CS degraded fast after 
the first 3 days, and this speed was significantly faster than 4% and 5% CS (one-way 
ANOVA, p = 2.37×10−6). However, after 14 days incubation, the final weight ratios were 
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not significant different (p = 0.09). These results show that the biodegradation ability of 
chitosan does not change with CS concentration. Simultaneously, weight ratios between 
CS (5%) and CS/HNTs (5% / 1%–5%, wt./wt.) were not significantly different (Figure 
2-2 B). The addition of HNTs did not affect CS biodegradability. 
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(A) 
  
(B) 
 
Figure 2-2: Biodegradability of CS and CS/HNTs in a lysozyme solution (1mg/ml). 
(A). The weight ratio of hydrogel beads consisted of pure chitosan (3%–5%). (B). The 
weight ratio of hydrogel beads consisted of 5% CS with different ratios of HNTs 
(1%–5% wt./wt.). 
 
  
20 
2.3.3 Tensile Property 
CS and CS/HNTs hydrogels (10 mm × 20 mm × 0.02 mm) were subjected to 
uniaxial testing using a CellScale Univert™ material testing device at a speed of 
10mm/min (Figure 2-3 A, B). As expected, higher chitosan concentrations imparted 
higher tensile stress resistance (σ), which is represented as MPa, while a lower 
concentration provided higher elongation (ε) represented as strain (%) in Figure 2-3 A. 
The addition of HNTs (2% w/v) enabled higher force loading but reduced elongation. 
When 5% chitosan was mixed with HNTs at different ratios (from 1% to 5% w/v), a 
lower concentration of HNTs increased the nanocomposites tensile strength and 
elongation, while this reinforcement decreased with increasing HNT addition. When the 
HNTs were increased to 5%, the CS/HNTs nanocomposite showed even weaker 
resistance than pure chitosan (Figure 2-3 B).  
The Young’s modulus values were calculated as 𝜎/𝜀. Based on three repetitive 
measurements, the average values and standard deviation of Young’s modulus were 
calculated, and the differences were compared and are presented in Figure 2-4. A one-
way ANOVA analysis demonstrated a significant difference in Young’s modulus among 
the different chitosan concentrations (p = 0.00002) supporting the conclusion that 
chitosan concentration is a crucial factor affecting Young’s modulus.  In addition, HNT 
addition significantly improved the tensile strength of CS, (p = 0.038, 3% CS vs. 3% 
CS/2% HNTs; p = 0.001, 4% CS vs. 4% CS/2% HNTs; p = 0.00006, 5% CS vs. 5% 
CS/2% HNTs). However, increases in tensile resistance after HNT addition gradually 
decreased as the concentration of HNTs increased to 5%, there was a weakening in 
hydrogel material properties. 
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(A) 
 
(B) 
 
Figure 2-3: The stress-strain profile of CS and CS/HNTs. (A) Tensile test of pure 
chitosan (CS) with the HNT additive groups (CS/HNTs). In this graph, every 
CS/HNT compound has a higher stress value compare to CS group. (3% CS/2% 
HNTs > 3% CS, 4% CS/2% HNTs > 4% CS, 5% CS/2% HNTs > 5% CS). 
Simultaneously, a higher concentration of chitosan showed higher stress values (5% > 
4% > 3%), however, the strain values displayed a different response (5% < 4% < 3%). 
(B) 5% CS/1% HNTs showed a major improvement in elongation, while 5% CS/2% 
HNTs showed the greatest improvement in strength. Increasing the number of HNTs 
gradually decreased its reinforcement ability, until at these concentrations (CS/HNTs 
(5% CS/ 5% HNTs), the nanocomposites was weaker and more fragile than pure CS. 
The stepwise failure behavior (slippage) at the end of each profile represents the 
fracture point of each specimen. 
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Figure 2-4: Young’s Modulus values of CS and CS/HNTs. (A) Different 
concentration of chitosan (3%–5%) and their combination with 2% HNTs 
wt./wt. (B) 5% CS combine with HNTs at different ratio (1%–5%). The 
changes are similar to the stress-strain profile. Young’s modulus value 
increased with HNTs increasing at low concentration (1%, 2%), as HNTs 
over 3% in composition Young’s modulus value decreased significantly. 
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2.3.4 Swelling Ratio 
Swelling behavior is a consequence of the interaction between a hydrogel and 
water. The rate of swelling is determined by several of the hydrogel’s physicochemical 
parameters, including its porosity, the nature of its porous structure, and the interactions 
between its polymer chains and the water molecules. A higher swelling ratio indicates 
more free volume exists in the hydrogel, and the free volume between knots are affected 
by the crosslink density. Thus, swelling ratio is also used to measure crosslink density. In 
this study, swelling ratio was calculated using the fractional increase in the weight of the 
hydrogel. In Figure 2-5, after 1, 3, and 5 days incubation, the swelling ratio of low 
chitosan concentration (3%CS) is significantly higher than the hydrogel that is composed 
of high chitosan concentration (3% CS> 4% CS> 5%CS). The addition of HNTs 
significantly reduced hydrogel swelling ratio (3%CS >3%CS + 2%HNTs, 4%CS > 4%CS 
+ 2%HNTs, 5%CS >5%CS+2%HNTs). Thus, lower concentration of chitosan had less 
crosslink density, and the addition of HNTs increased the crosslink density. Furthermore, 
the swelling ratio change indicates that the porosity and porous structure were also 
affected by chitosan concentration.  
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Figure 2-5: Swelling ratio for each hydrogel. The overall changes are presented in 
summary figure (A). The swelling ratio for Day 1, Day 3 and Day 5 (B–D, 
respectively). The symbol **** indicates a significant difference (p < 0.0001, n = 3). 
Error bar represents standard deviation. 
2.3.5 Drug Release 
Gentamicin was selected as a model for drug release. The final drug loading 
efficiency of gentamicin loaded into HNTs was 13.96 ± 1.1%. The pattern of gentamicin 
release from the chitosan/HNT beads was used to validate what composition would serve 
optimally as a drug delivery system. As Figure 2-6 illustrates, gentamicin released from 
HNTs had a burst release in the first 10 hours, while CS/HNTs provided a more stable 
and extended drug release profile. According to one-way ANOVA analysis, differences 
in drug release capability among 3% CS, 4% CS, and 5% CS at first 56 hours were not 
statistically significant, but at 104 hours, there was a significant difference between them 
(p = 0.018<0.05), according to Turkey’s multiple comparisons test, 5% CS is significant 
different from 3% CS and 4% CS, which indicates high concentration of chitosan could 
provide a longer drug release time. 
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Figure 2-6: Accumulated drug release profiles for CS/HNTs hydrogels and pure drug 
loaded HNTs. Every group contained the same amount of drug loaded HNTs. 
2.3.6 Live/Dead Assay 
The Live/Dead assay was applied to pre-osteoblast cultures as a means for 
estimating the cell viability after exposure to the chitosan and chitosan/HNT composite 
films. Cell cultures were then photodocumented and the fluorescently-labeled cells also 
provided an excellent opportunity to observe and record cell adhesion and spreading. As 
the graphs in Figure 2-7 show, when compared to control culture wells, cells cultured on 
CS/HNTs substrates showed excellent cytocompatibility with little cytotoxicity. 
Observed cellular behavior is not significantly different among control and hydrogel 
groups with the exception of the 3% CS and 3% CS/ 2%H (H is short for HNTs) groups. 
Cells cultured on these films appeared to cluster and form small colonies (Figure 2-8). 
This behavior may due to surface features or physicochemical properties of the films. As 
is shown in Figure 2-9, among three different concentrations, 3% chitosan has more 
wrinkles. This observation is consistent with what we found above: a lower concentration 
of chitosan had weaker mechanical properties. When cell culture plates were coated with 
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different concentrations of chitosan, lower concentrations of chitosan also presented a 
reduced degree of stiffness as observed during manual handling of these films. 
Furthermore, it was more difficult for the softer material to maintain its scaffold 
structure. During the crosslinking process, multiple micro-scale wrinkles were formed in 
3% CS and 3% CS / 2% HNT hydrogels. The substrate surface features and 
physicochemical properties may have cellular behaviors resulting in the observed cell 
clusters Figure 2-7.  
 
Figure 2-7: Antibacterial test on E.coli (A) and S. aureus (B). The absorbance values 
at 630 nm for: pure bacteria suspension (broth + E. coli, broth + S. aureus); CS/HNTs 
without antibodies (3%+H, 4%+H, 5%+H), CS/HNTs with antibodies (3%+H+G, 
4%+H+G, 5%+H+G). Error bar with standard deviation. (* p < 0.05; ** p < 0.005; 
**** p < 0.00005, n = 3). 
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Figure 2-8: Live/Dead Assay of cells cultured on CS and CS/HNTs. Compared to 
control, there are live cells (green) are observed on the film-coated plates, but the 
number of dead cells (red) has increased as compared with the control plate but 
remain few in number. This indicates cells can adhere and proliferate on CS and 
CS/HNTs substrate. However, cellular morphology was influenced by the surface 
features and physicochemical properties of substrate. 
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Figure 2-9: Picture for chitosan films after they were crosslinked and dried. The 
red arrows point to the wrinkles on the film. 
  
2.4 Discussion 
The goal of this study was to fabricate a nanoclay-enhanced hydrogel for use as a 
biodegradable drug delivery system. Critical in our design was to produce hydrogel films 
with suitable strength enabling a range of application such as topical application or 
injection. Clay nanoparticles are present in nature in several different morphologies 
depending on the nature of their layered structure. Clay nanoparticles are being actively 
studied for their potential in a variety of biomedical applications, in particular, drug 
delivery. The most well-known of these nanoparticles include kaolinite, montmorillonite, 
and halloysite 67,68. Kaolinite is an abundant and inexpensive clay mineral and has a long 
history in drug delivery applications 69. Kaolinite has been used in many pharmaceutical 
applications either as an excipient or an active ingredient because of its excellent 
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physical, chemical, and surface physicochemical properties 68,69. Its application within 
composite drug delivery systems include antimicrobial 70, anticancer 71, skeletomuscular 
and geriatric diseases 69 as well as a bioactive agent for the treatment of some common 
diseases. Kaolinite and chitosan nanocomposites have seen significant research activity 
72,73.  
Montmorillonite clay (MMT) belongs to the smectite group with tetrahedral silica 
sheets layered between alumina octahedral sheets at a ratio of 2:1, respectively 74. It has a 
large specific surface area, exhibits good absorbance ability, high cation exchange 
capacity, adhesiveness, and drug-carrying capability 73,74. Drug incorporation into MMT 
can occur by adsorption both within its interlayer-spaced structure, by replacement of the 
water molecules, and on the surface. The most important interactions taking place 
between the two components of the hybrid system are ionic 74,75. Chitosan MTT 
composites have developed as drug delivery systems for antimicrobial 76, cancer 77, 
gastrointestinal 77, osteoarthritis 78, and wound healing applications 79. Emerging in 2012 
as a potent nanocarrier and nanocontainer, halloysite is tubular aluminosilicate 
nanoparticle that has been under intense study as an agent for the sustained release of 
antibiotics, chemicals, chemotherapeutic agents, and growth factors 74,75. HNTs typically 
display an inner diameter ranging from 15 to 50 nm, an outer diameter ranging from 30 to 
50 nm, and lengths between 100 and 2000 nm 80–82. HNTs have been shown to serve as a 
nanocontainer with vacuum-trapped drugs, bioactive agents, and other substances, and 
these are released in a sustained manner 83–86.  
In this study, the effects of chitosan and HNTs concentration and combination 
ratios of these materials on the mechanical properties of a hydrogel composite and its 
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drug release capability were analyzed. Our results suggest that a higher chitosan 
concentration produced a more uniform bead shape and a greater drug release capability. 
Other studies have shown that ionic gelation [63,64] (Al3+, Ca2+, and Zn2+) or chemical 
cross-linking 87,88 can also produce strong beads with a more spherical shape. Lower 
concentrations of chitosan and HNTs produce beads that were very soft and irregular in 
shape.  
Higher chitosan concentration also created a hydrogel with smaller pore sizes. 
Hydrogels with smaller pores were also less deformable than gels with larger sized pores. 
A similar finding was reported by Chiu et al., (2013) with poly (ethylene glycol)-co-(l-
lactic acid) hydrogels 89. To verify this potential explanation, we took the cross-section 
SEM images for the hydrogel beads. In Figure 2-10, both 4% and 5% chitosan and their 
HNTs composite hydrogels have numerous small pores. There is no significant different 
in pore size between 4% and 5% chitosan and its HNTs composites. However, 3% 
chitosan and its HNTs composite hydrogels have numerous bubbles instead of pores, and 
the bubbles are much larger than the pores formed in 4% and 5% chitosan hydrogels. 
Those bubbles were formed during the drying process. If all the bubbles break, larger 
pores remain. This observation partly supports our hypothesis.  
As expected, the deformability decreased with diminishing of polymer content, 
since polymer content has an influence on cross-link density. This finding agrees with 
other two literatures 90,91. The mechanical properties also diminished rapidly during 
incubation, suggesting a bulk mechanism of degradation, which is consistent with our 
swelling (Figure 2-5) and pore size observations (Figure 2-10). The addition of HNTs to 
chitosan did not affect pore structure or porosity of the scaffolds, a result also reported by  
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Liu et al.. 49 
The objective of the degradation study was to determine whether the HNTs 
addition inhibited or increased chitosan degradation. Our research showed no significant 
effect with HNT addition on degradation, indicating that the stability of the 
chitosan/HNT and the predictability of biodegradation rates depend on the final 
composites. As anticipated, HNT addition contribute to improve chitosan hydrogel tensile 
properties. In two previous studies, HNT addition to the chitosan matrix also significantly 
enhanced compressive strength, compressive modulus, and thermal stability 66,88. HNTs 
are widely used as a polymer bulk filler added to significantly improve the mechanical, 
swelling, water uptake, thermal, drug-loading efficiency of the composite matrices 7,49,56. 
In this study, however, when HNT concentration exceeded a threshold value, 
hydrogel deformability decreased sharply. A 2% wt./wt. combined ratio showed the best 
 
Figure 2-10: SEM images of cross-section for different hydrogel composites. The arrows 
in the picture of 3% chitosan (3%C) and its HNTs composites (3%CS + 2%HNTs) point 
to the example of bubbles. The arrows in the picture of 4% chitosan (4%C) and 5% 
chitosan (5%C) and their hydrogel composites (4%CS + 2%HNTs and 5%CS + 2%HNTs) 
point to the example of pores. 
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response to tensile testing. The results of degradation can also be explained along the 
same lines. The 2% wt./wt. HNTs-chitosan hydrogels also showed the slowest rate of 
degradation. Our observation of HNT response to deformability may be caused by 
inadequate dispersion of HNTs in the chitosan matrix 37. The interfacial binding between 
HNTs and chitosan is achieved by hydrogen bonding and electrostatic interactions 49. A 
uniform dispersion results in a uniform interfacial-binding matrix, which is favorable to 
force conduction. In contrast, too many nanotubes inhibit the dispersion state and create 
interfacial gaps, which are easy to break. This phenomenon is clearly presented in Figure 
11: 5% chitosan combined with HNTs at different rations (1% to 5%), HNTs clusters 
were observed by SEM. The hydrogel films with higher concentration HNTs have larger 
and more HNTs clusters. Those clusters resist the force conduction and may result in 
gaps, which is shown in the insert picture of Figure 2-11 4% HNTs. Instead of 
reinforcing the biomaterials, exceeded addiction of HNTs weakened the biomaterials 
original mechanical properties.  
In terms of the chitosan/HNT composite’s potential as a drug delivery system, the 
results of the drug release profile analysis showed a doped drug could be released in a 
sustained fashion, and bacteria growth inhibition tests indicate that the release of 
gentamicin was able to inhibit bacterial growth. In summary, the chitosan-HNTs hybrid 
hydrogel exhibited better mechanical properties than pure chitosan hydrogels, and their 
combination showed a more sustained ability in drug release. Chitosan and HNTs are 
eco-friendly and biocompatible materials 44,45,51,54,55, and with increases in their 
mechanical properties, they will have increased use in clinic treatments. For instance, 
coating implants and providing a long-term drug delivery to prevent wound infection. 
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Furthermore, instead of antibiotics HNTs could be loaded with growth factors designed 
to direct cell migration by chemotaxis or induce differentiation. 
 
Figure 2-11: SEM images of hydrogel surface that consisted by 5% chitosan and 
combined with HNTs at different rations (1% to 5%). The pictures in the right corner are 
the zoom in pictures of the selected areas. 
2.5 Conclusions 
Chitosan-based hydrogels are being used for their biodegradable properties and 
their ability to that mimic the extracellular matrix of many tissues. However, the use of 
chitosan hydrogels has been limited by their inherent mechanical weakness. This study 
examined the effects of increased chitosan and HNT concertation on selected mechanical 
properties of chitosan/HNT hydrogels, with and without gentamicin addition. HNTs are 
widely employed as a bulk filler to improve the performance characteristics of many 
polymers. HNTs have also been shown to be a viable nanocontainer able to provide 
sustained release of antibiotics, chemicals, and growth factors. The addition of HNTs to 
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chitosan hydrogels improved the gels’ mechanical properties. Chitosan/HNT gentamicin-
doped hydrogels enabled sustained drug release and were effective in reducing bacterial 
growth. Our doped clay/chitosan nanocomposite may overcome the limitations of 
traditional anti-bacterial hydrogels by providing a focal drug delivery and sustained 
release of drugs, singly or in concert, or a suite of drugs or drug/growth factor 
combinations. 
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CHAPTER 3 
BI-FUNCTIONALIZED HNTS: CELLULAR UPTAKE ANALYSIS 
AND CHEMOTHEREUTIC POTENTIAL 
3.1 Introduction 
Cancer is the second leading cause of death in the United States 92. While 
radiation and surgery treatments have advanced cancer treatment, chemotherapy is still 
one of the leading treatment modalities 93. Unfortunately, current chemotherapeutic 
agents adversely affect healthy cells at the target site as well as elsewhere in the body 94. 
Chemotherapy drugs work by impairing cell division and are effective treatments for 
early-stage tumors when cancer cells are rapidly multiplying. However, they also produce 
a range of unpleasant side effects. Systemic toxicity is an undesired consequence for the 
majority of chemotherapeutic drugs 92 93. The development of a multi-functional drug 
delivery system (DDS) that can provide extended, controlled, and selective drug release 
is at the forefront of current cancer therapy research 9394. Targeting chemotherapeutic 
drugs directly at the tumor cells would increase drug effectiveness and reduce side 
effects.  
Recent advances in nanoparticle (NP) research have shown promise in 
remediating many of these adverse effects 95–97. A key challenge for scientists is to design 
cancer nanoparticles that target cancer cells only and are retained at tumor sites. 
Cytotoxic chemotherapies have a narrow therapeutic window, with high peaks and 
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troughs of plasma concentration. Novel nanoparticle formulations of cytotoxic 
chemotherapy drugs can enhance pharmacokinetic characteristics and facilitate passive 
targeting of drugs to tumors via the enhanced permeability and retention effect, thus 
mitigating toxicity 96,97. By design, these nanoparticle types can directly carry cancer 
drugs to cancer tumors, thereby improving the ability to kill cancer cells and hence 
leading to more effective treatment outcomes. Nanoparticle currently in clinical use or 
undergoing clinical investigation for anticancer therapies include liposomes, polymeric 
micelles, protein-drug nanoparticles, and dendrimers 98,99. Surface modification of NPs 
with suitable ligands or targeting agents has the potential to improve therapeutic efficacy 
and reduce the unwanted side effects of systemic delivery 100,101. Recent studies on the 
interaction between surface-functionalized nanoparticles and animal cells have shown 
great potential for using these nanomaterials for various biomedical and biotechnological 
applications, such as cell type recognition, disease diagnosis, intracellular imaging, and 
drug/gene delivery.  
Multifunctional nanoparticles, with both diagnostic and therapeutic functions, 
show great promise towards personalized nanomedicine. Folate receptors (FRs) are 
overexpressed in numerous cancers but are under expressed or nonexistent in most 
normal tissues. Thus, folic acid is considered as one of the best-characterized ligands to 
use in targeted drug delivery. Halloysite nanotubes (HNTs) have been widely studied as a 
drug carrier as they provide sustained drug release for a variety of bioactive factors. 
Halloysite nanotubes are naturally occurring nanotubes composed of silica and alumina 
102. They typical inner diameter, outer diameter, and length of these tubes are 1-30 µm, 
30-50 nm, and 100-200 nm, respectively 82. Halloysite nanotubes have a large external 
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surface area and an internal pore volume capable of encapsulating and delivering large 
quantities of biogenic molecules. HNTs were chosen as they are an effective 
nanocontainer and nanocontainer that can entrap a range of bioactive agents and drugs 
within the inner lumen or in an outer coating for film, followed by their sustained release 
51,103,104. 
An essential aspect of HNTs that allows these nanotubes to be considered in the 
design of a multi-functional DDS is their lack of cytotoxic effects 105. Halloysite 
nanotubes were added to different cell cultures for toxicity tests. The data showed that 
HNTs had low cytotoxicity, rendering it a suitable candidate for household materials and 
medicine 81. In another study, HNTs were added to cultures of epithelial adenocarcinoma 
and human breast cancer cells up to a concentration as high as 75µg/mg, and cell 
proliferation was not affected 54. HNTs have also shown biocompatibility in other 
organisms such as Caenorhabditis elegans (C. elegans) and did not appear to cause any 
damage to cell organelles 106,107. All these studies support the observation that HNTs can 
be placed within an organism without any observable adverse side effect 108,109. 
Surface modification of HTNs for drug delivery purposes has also seen significant 
research interest 109,110. One widely used for HNT surface modification is the addition of 
silanes to the surface 111,112. In contrast, the area of chemical modification of HNTs via 
covalent bonding, is an area that has seen only a few studies using bioactive molecules 
110. Covalently functionalized halloysite nanotubes have molecules grafted onto the HNTs 
surface 111,112. In a previous study, a method was developed to attach folic acid (FA) to 
the HNT surface with the addition of a second molecule, of fluorescein isothiocyanate 
(FITC) to create a bi-functionalized HNT (b-HNT) 113. The bHNT were characterized by 
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FTIR, 13C CPMAS NMR spectrum, and UV-Vis, and the data demonstrated that folic 
acid (FA) and ﬂuorescein isothiocyanate (FITC) covalently bonded to the HNT surface 
113. 
Conjugation of NPs with antibodies and ligands such as folic acid (FA) allows for 
the specific targeting of NPs to the cancer cells, which overexpresses the receptor for the 
targeting ligand 114,115. Numerous studies have shown that FA is an attractive targeting 
agent which is specific to the FA receptors (FRs) 116,117. FA receptors are overexpressed 
in several cancers such as in breast, brain, colon, lung, kidney, and cancers 117,118. The 
expression level of FA receptors is around 150–300 times more than that of the healthy 
tissues 118,119. Folic acid (FA), an oxidized form of folate, can bind to FRs and increase 
cellular uptake in cancer cells, while the FA receptor is poorly expressed in healthy 
tissues. Owing to this distinguishing property, FA has emerged as a suitable targeting 
agent for cancer treatment 116. 
With tailored surface modification, HNTs can be developed into a targeted drug 
delivery system 120–122. In our design of a bi-functionalized HNT (b-HNT) drug delivery 
system, FA would allow for selective targeting of tumors while the effectiveness of the 
targeted system can be determined via a second ligand, FITC, for imaging 113. We tested 
our b-HNT for cell viability, proliferation, cell uptake efficiency and, the ability to 
deliver an anti-tumor agent, methotrexate (MTX). MTX is a folic acid antagonist and it 
has a therapeutic effect on many cancer types. It is widely used as a major 
chemotherapeutic agent for lymphoblastic leukemia, lymphoma, osteosarcoma, and 
breast, lung, head, and neck cancers 123–125. 
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In this study, colon cancer cells (CT26WT) were used to assess the proper dosage 
of bHNT. Cell viability decreased below 80% at high dosage (150 mg/ml), the cause of 
cell death was further analyzed. We also found that the size of nanoparticle has a 
significant effect on cells uptake efficiency. Extracellular particles get into cells mainly 
through clathrin- and caveolae- dependent endocytosis. Two inhibitors chlorpromazine 
(CPZ) and filipin were used to disrupt clathrin- and caveolae- dependent endocytosis, 
respectively. The fluorescent signals express by cells were measured to confirm the cell 
uptake mechanism for bHNTs. Observations made by multi-photon microscopy indicated 
that bHNTs were present and distributed throughout the cellular cytoplasm inside the 
cells. Methotrexate was loaded into the bHNTs lumen and delivered into cells. One 
untransformed cell line, preosteoblast (MC3T3-E1), and two cancer cell lines, colon 
cancer cells (CT26WT) and osteosarcoma (K7M2 WT), were selected to assess bHNTs 
target ability and drug efficiency.  
3.2 Materials and Methods 
3.2.1 Materials 
All cell culture materials and reagents were purchased from Sigma Aldrich, St. 
Louis, MO. Cell culture dishes, pipettes and other disposable plastics were purchased 
from Mid Sci, St. Louis, MO. CT-26 murine colorectal cancer cells.  
 
3.2.2 Production of Shortened HNTs 
10 g of commercially purchased HNTs were immersed in 50 ml PBS for 24 hours 
and ultra-sonicated for 30 mins by Qsonica Sonicators at 70% power. After they were 
relaxed for 30 mins, HNTs were ultra-sonicated for another 30 minutes. Then the mixture 
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was transferred to 50 ml centrifuge tube and centrifuged at 100 g for 10 minutes. The 
deposition was collected and dried at 60 °C for 2 days. 
 
Figure 3-1: The process of short HNTs fabrication. 
3.2.3 FA/FITC-HNTs Synthesis 
The FA/FITC-HNTs were synthesized by the same methods as our previous 
study. Briefly, HNTs were reacted at reflux with N-[3-(trimethoxysilyl)propyl] 
ethylenediamine  (DAS) in toluene for 24 hours. Then, the HNT-DAS composite was 
reacted with FA in the presence of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide 
(EDC) in DI water overnight. Finally, the complex reacted with FITC in acetone 
overnight. Between each step, the complex was washed and filtered by using methanol, 
sodium chloride solution, sodium bicarbonate solution, and distilled water (DI) water.  
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Figure 3-2: Schematic representation of the conjugation of both FA and FITC to DAS 
which is attached to the surface of the HNTs. Methotrexate (MTX) was doped into the 
HNT lumen. DAS =N-[3-(trimethoxysilyl)propyl) ethylenediamine, FA = folic acidity 
= fluorescein isothiocyanate. 
3.2.4 FA/FITC-HNTs Characterization 
The infrared spectrum (FTIR) was recorded at a resolution of 4s-1 with 16 scans 
using a Thermo Scientific NICOLET™ IR100 FT-IR Spectrometer (Thermo Fisher 
Scientific; Waltham, MA). Thermo Scientific OMNIC™ software was used to study the 
stretching bands.  
SEM images of original size of HNTs and shortened HNTs were analyzed by 
ImageJ and also used to measure particle size. 
3.2.5 Cell Culture 
Cytotoxicity of functionalized (coated) HNTs were studied in CT26-WT murine 
colorectal cancer, K7M2-WT osteosarcoma cells, and MC3T3-E1 preosteoblast cells. All 
cells came cryopreserved from ATCC. Cryovials were thawed and allowed to equilibrate 
in a water bath, all the cells were cultured in 25 cm2 tissue culture flask and incubated at 
37°C under humidified 5% CO2 and 95% air. CT-26 cells were cultured in RPMI 1640 
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medium containing 10% FBS and 1% penicillin (complete medium). Osteosarcoma cells 
were fed by complete DMEM containing 10% FBS and 1% penicillin. Preosteoblast cells 
were incubated in complete alpha-MEM containing 10% FBS and 1% penicillin. 
Subconfluent cells were passaged with 0.25% trypsin, collected by centrifugation, 
suspended in cell culture medium and cultured at a 1:4 split into 25 cm2 tissue culture 
flasks. All three types of cells underwent passage four before use.  
3.2.6 MTS Assay 
Cell proliferation ability affected by HNTs and FA/FITC HNTs were assessed by 
MTS assay. Cells were seeded into 48-well plate at a concentration of 1 X 105 cells/ well 
and cultured for 24 hours. Different amounts of pure HNTs or functionalized HNTs were 
added into cell culture plates (0, 50, 100, 150, 200, 250 µg/ml). 40 µl MTS stock solution 
were added to each well and cultured for 2 hours at 37 °C in darkness. 200 µl of 
supernatant of each sample were transferred to 96-well plates and absorbance values were 
read at 490 nm by microplate reader.  
3.2.7 XTT Assay 
The cytotoxicity of HNTs and FA/FITC HNTs were studied by XTT Cell 
Viability Assay Kit (BIOTIUM). Cells were cultured and treated following the same 
procedure as MTS assay. 100 µl of cell suspension were added into 96-well tissue culture 
plates, then added 25 µl activated XTT solution were added and the combination were 
incubated for 2 hours. Absorbance values were measured at 450nm; background 
absorbance was measured at 630nm. The final normalized absorbance values were 
obtained by subtracting background absorbance from signal absorbance.  
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3.2.8 Cell Uptake Efficiency 
CT26WT, murine colorectal cancer cells, were selected to assess cell uptake 
efficiency. Cells were seeded into 48 wells at concentration of 1.5´105 cells/well and 
incubated for 24 hours. Then, biofunctionalized FA/FITC-HNTs were added into cell 
culture medium at a finial concentration of 25 µg/ml and incubated for another 24 hours. 
Cell fluorescent intensities were measured by fluorescent microplate reader at 490/525 
nm (Ex/Em) at designed time points. Before measuring, cells were washed with fresh 
RPMI 1640 3 times to wash away FA/FITC-HNTs that did not uptake by cells. The cell 
numbers were measured.  
3.2.9 Cell Uptake Mechanism 
CT26WT cells were seeded into 24 wells at concentration of 2´105 cells/well and 
cultured for 24 hours. Two inhibitors chlorpromazine and filipin were selected to assess 
cell uptake mechanism. Cells were pre-cultured with chlorpromazine (CPZ) (7 µg/ml) or 
filipin (5 µg/ml) for 2 hours. Cells treated without any inhibitor served as the control. 
FA/FITC-HNTs (25 µg/ml) were added to each well and incubated for another 24 hours. 
Fluorescent intensities expressed by cells were measured as above. 
3.2.10  Multi-photon Image 
CT26WT cells were seeded on a glassed slide at a concentration of 1´105 cells/ml 
and cultured for 24 hours. FA/FITC-HNTs were added into cell culture plate (25 µl/ml) 
and continually incubated for 12 hours. DiOC18(7) (DiR) (ThermoFisher Scientific) 
working solution were prepared by following the company protocol. Cells were washed 
by DPBS for 3 times, then DiR working solution was added into each cell culture well (1 
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µg/ml) and incubated for 2 hours. Then cells were fixed by 4% paraformaldehyde for 
multi-photon images.  
 
Figure 3-3: Schematic representation of multi-photon images. 
3.2.11 Apoptosis and Necrosis 
In our previous study, FA/FITC-HNTs at high concentration, 150 ug/ml, 
significantly reduced cell viability below 80%. The mechanism of cell death was further 
analyzed by Annexin V-FITC Apoptosis Kit (BioVision). In brief, Ct26wt cells were 
seeded into 24 wells at a concentration of 2´105 cells/well and cultured for 24 hours. 
Then, a large amount of FA/FITC-HNTs was added into cell culture medium (150 µg/ml) 
and incubated for 24 hours. Then 3´105 cells were collected and suspended in 500 µl of 
1X Binding Buffer, then mixed with 5 µl of Annexin V-FITC and 5 µl of propidium 
iodide. Cell suspension mixtures were incubated in a dark environment at room 
temperature for 5 minutes. Then samples were examined by flow cytometry at 
488/530nm (Ex/Em).  
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3.2.12 Drug Loading 
Methotrexate was dissolved in PBS (1mg/10ml) and stirred with FA/FITC-HNTs 
(200mg) for 12 hours. Then, the mixture was vacuumed for 24 hours and centrifuged. 
The bottom deposited FA/FITC-HNTs were collected and washed by PBS for 3 times 
and air-dried. The supernatant liquid was collected and stored at -20 °C for drug loading 
efficiency determination.  
3.2.13 Drug Loading Efficiency and Drug Release 
20 mg of drug loaded FA/FITC-HNTs were added into 2ml PBS. 1 ml of PBS 
was collected at certain time period and replaced by 1ml of fresh PBS. The collected 
samples were stored at -20 °C until they were measured by MTX Elisa kit (ENZ-KIT 
142-0001, Enzo Life Science). Drug loading efficiency were determined by the following 
equation:  
Loading	Efficiency = total	amount	of	MTX − supernatant	MTXtotal	amount	of	MTX × 100% Equation 3-1 
3.2.14 Target Specific Cancer Cells and Inhibit Cancer Growth 
Methotrexate-loaded FA/FITC-HNTs (50ug/ml) were cocultured with murine 
colorectal cancer (CT26WT), osteosarcoma cells (K7M2WT), and pre-osteoblast cells 
(MC3T3-E1) separately at 48 wells tissue culture plates (1´105 cells/well). After 24hours 
incubation, cell viability of each cell type was assessed by MTS agent as above (3.2.6). 
Cells cultured without HNTs served as the control.  
3.2.15 Statistical Analysis 
Data were obtained from 3 parallel experiments and are expressed as mean ± 
standard deviation (S.D.). Each experiment was repeated 3 times to check the 
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reproducibility if not otherwise stated. Statistical analysis was performed by two-tailed 
Student’s t-tests between two groups. The significant level was set as p<0.05.  
3.3 Results 
3.3.1 Proper Dosage Determination 
The fabrication method of FA/FITC-HNTs (bHNT) was reported in our previous 
study, 113 in which we did a live/dead assay and found that cell cytotoxicity was increased 
with bHNT loading concentration. In order to confirm the proper dosage range of bHNT, 
we employed MTS assay and XTT assay to assess cell proliferation and viability when 
cells co-cultured with pure HNTs and bHNT at different concentrations. Both tests 
presented similar results: cell viability changed with the concentration of HNTs 
nanoparticles. In the MTS assay (Figure 3-4 A, B), cell proliferation was improved when 
the concentration of nanoparticles was below 100 µg/ml, but when the concentration 
increased to 150 µg/ml, the proliferation ability significantly decreased 20%. The XTT 
assay showed the similar results (Figure 3-4 C, D), cell viability decreased with the 
increasing concentration of HNTs. But the XTT assay showed that CT26WT cells have a 
higher tolerance concentration to HNTs, the significant cytotoxicity exhibited above 200 
µg/ml. Both results suggested that the highest dosage of bHNT is 150 µg/ml. 
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Figure 3-4: CT26WT cells cultured with pure HNTs (A) and bHNT (B) at different 
concentration then applied with MTS assay. Cell proliferation ability at each different 
concentration was calculated by comparing to the control group. CT26WT cells 
cultured with pure HNTs (C) and bHNT (D) at different concentration then applied 
with XTT assay. Cell viability at each different concentration was calculated by 
comparing to the control group. (error bar with standard deviation, n=6). 
3.3.2 Nanoparticle Size Determination 
Halloysite nanotubes are naturally formed nanoparticles, their original length is 
around 1-1.5 µm. Recent studies have used shortened HNTs 66,115,126. Rong et al. 
introduced a detailed procedure to produce homogeneous and length controllable HNTs 
127. Thus, we hypothesize different sizes of HNTs would affect cell behaviors. Due to the 
low production of Rong’s method, which is less than 1%, we fabricated the short HNTs 
in another way for larger yield. Dynamic light scattering (DLS) is the most commonly 
used technique to determine nanoparticle size, however, DLS prefers to analyze spherical 
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nanoparticles instead of virgate nanotubes. Thus, we took the SEM of the HNTs and used 
Image J to measure their size and plotted the data into histogram graph (Figure 5). As it 
shown in Figure 3-4, the lengths of commercially-purchased HNTs were distributed in a 
wide range, the average size is 0.914±0.45 µm, n=102 (Figure 3-5 A), while the size of 
short HNTs focus on 0.715± 0.25 µm, n=80 (Figure 3-5 B). Compared the two different 
sources of HNTs, we can easily find the size distribution of shortened HNTs are more 
concentrated, which means they are more homogeneous. Size controlled nanoparticles 
could help to reduce the manual errors and provide accurate evaluation of its application 
in biomedical researches. 
 
Figure 3-5: Histogram graph of size frequency of long HNTs (A) and short HNTs (B).  
3.3.3 Cell Interaction to Long and Short HNTs 
In our hypothesis, the size of HNTs would affect cell reaction to biofunctionalized 
HNTs. Cell uptake efficiencies of two difference size of HNTs were analyzed. 
Fluorescent intensity of cells (cell number = 4.46´105 ± 0.063´105) were detected after 
24 hours incubation (Figure 3-6 A). We monitored the fluorescent intensity changes in 
24 hours. Cellular uptake efficiency for both size of HNTs exhibited similar changes 
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along with time. In the end, more amount of short-HNTs are detected in cells, which 
indicates smaller size of HNTs are more easily to be absorbed by cells.  
3.3.4 Apoptosis & Necrosis 
Our previous cell cytotoxicity study had shown that cell viability significantly 
decreased when the concentration of HNTs reached to 150 µg/ml. In order to distinguish 
cell death mechanism, apoptosis or necrosis, we did a further study by incubating 
CT26WT cells with long and short bHNT and applied with Annexin V-FITC Apoptosis 
Kit. Fluorescents signals of apoptosis and necrosis were assessed by flow cytometry. As 
Figure 3-6 B and C shows, in cells cultured with long bHNT, 20%±1.5% of cells death 
was caused by apoptosis and 10%±0.5% was caused by necrosis; cells cultured with short 
bHNT led to 23%±1.3% in apoptosis and 13%±0.6% in necrosis. Thus, apoptosis takes 
the main role in cell death. In addition, short bHNT results in a higher cell death 
percentage. This interesting finding leads us to think about the results of cell uptake 
efficiency. As shown above, cells accumulated shorter bHNT inside their body compare 
to long bHNT, and short bHNT results in more cells death. This phenomenon indicates 
that excessive accumulation of bHNT inside cells lead to apoptosis.  
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Figure 3-6: A. Fluorescent intensity of FITC detected from CT26WT cells after 24 
hours incubation (cell number for each test = 4.46´105 ± 0.063´105, each group had 9 
tests, error bar with standard deviation). B. CT26WT cells co-cultured with long or 
short bHNT, death caused by apoptosis and necrosis were assessed by flow cytometer. 
(cell number for each test =3´105, each group had 6 tests, error bar with standard 
deviation) C. Flow cytometer observation applied with FITC filter for apoptosis (first 
row) and PE filter for necrosis (second row). Dead cells were in the right side of the 
shed line. Cell death percentage of apoptosis or necrosis was presented in the right 
corner of each graph.  
3.3.5 Endocytosis Mechanism 
After FA/FITC-HNTs binds to folate receptors, it may initiate cellular uptake 
mechanisms in two different ways, clathrin-mediated endocytosis or caveolae-mediated 
endocytosis. Chlorpromazine (CPZ) can the ability to disrupt clathrin on the cell 
membrane; while filipin can inhibit caveolae formation. CT26WT cells were pretreated 
with those two inhibitors and co-cultured with bHNT, their final fluorescent intensity was 
compared to cells without inhibitor treatment. As the result showed in Figure 3-7 
illustrates, the addition of CPZ promoted HNTs absorption in first 12 hours, then the cell 
uptake ability decreased. On other hand, filipin presented an inhibition in whole testing 
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time period. This indicates cells absorption for FA/FITC-HNTs may mainly depend on 
caveolae-mediated endocytosis and assist with clathrin-mediated endocytosis. 
 
Figure 3-7: Fluorescent intensity of FITC included in cells that were pretreated by 
CPZ or filipin and cocultured with FA/FITC-HNTs for different incubation time. 
(error bar with standard deviation, n=6).  
3.3.6 Intracellular Location of bHNTs 
All above studies have shown bHNT were taken up by cells. In order to confirm 
the intracellular location of bHNT, we co-cultured CT26WT with bHNT for 24 hours, 
and stained the cell membranes with DiR, then detected the fluorescent bHNT by multi-
photon microscopy. As shown in Figure 8, the red circular rings represent cell 
membranes, and the yellow particles represent bHNT. Multi-photon pictures provided a 
3D picture of cells, according to the front view (Figure 3-8 A and D) and side view 
(Figure 3-8 B,C,E,F). These images show that some FA/FTIC- HNTs nanoparticles are 
embedded in cell membrane, and some of them are cell cytochylema. 
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Figure 3-8: Multi-photon pictures of cells after exposed to bHNT, pictures are 
analyzed by ImageJ. CT26WT cells co-cultured with bHNT for 24 hours, then DiR 
dye was added for another 2 hours incubation. Cell membranes were stained by DiR 
dye and exhibited a red color at wavelength of 850nm. At this wavelength FITC 
exhibited a yellow color. The red circular rings represent cell membranes, and the 
yellow particles represent bHNT. The 3D pictures were captured for 36 microns in z 
with a 2 micron in each z step. A is the front view of the 3D picture for multiple cells, 
B and C are the side view of the 3D picture. D, E, and F are the zoom in pictures of 
the marked cell.  
3.3.7 FTIR Analysis-Methotrexate and Drug Release 
The above experiments indicate that our functionalized HNTs were successfully 
taken up by colon carcinoma cells (CT26WT). As it designed as a drug delivery system, 
we selected methotrexate (MTX) as drug model and loaded it into our functionalized 
FA/FITC-HNTs. Methotrexate is a commonly used anticancer drug to osteosarcoma. 
However, it is well-known for severe side effects. A cancer target drug delivery system is 
a promising strategy to reduce side effects and improve drug efficiency.   
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The modification of FA/FITC-HNTs were detected by FTIR. Halloysite is an 
aluminosilicate clay mineral (Al2Si2O5(OH)4), the Si-O stretching vibrations and Al-OH 
vibrations were represented at 1000-1130 cm-1. Folic acid, FITC and MTX containing -
NH and -OH bonds, their characteristic absorption is in the range of 3300-3500 cm-1. The 
transmittance changes at 3300-3500 cm-1 indicated the successful grafting of FA, FITC, 
and MTX (Figure 3-9).  The loading efficiency of MTX into HNTs is 34.74% ± 3.5%, its 
drug release profile is presented in Figure 3-10. Even through a burst release occurred in 
the first 20 hours, this drug delivery system extended drug release time to more than 96 
hours.  
 
Figure 3-9: FTIR detection of pure HNTs (blue), HNTs-FA (purple), FA/FITC-HNTs 
(green) and FA/FTIC/MTX-HNTs (red).  
54 
 
Figure 3-10: Accumulated drug release profile of methotrexate in 96 hours. (Error 
bar with standard deviation, n=3).  
 
3.3.8 Cancer Target Drug Release 
The bHNT (FA/FITC-HNTs) were developed to deliver drugs to specific cancer 
cells. One untransformed cell line, preosteoblast (MC3T3-E1), and two cancer cell lines, 
colon cancer cells (CT26.WT) and osteosarcoma (K7M2 wt.), were selected to assess 
specific target ability of bHNT and drug efficiency on cell growth inhibition. The results 
are presented in Figure 3-11. Methotrexate is one of the most active drugs used to treat 
osteosarcoma, but it has multiple side effects. In our study, methotrexate-loaded bHNT 
(FA/FITC/MTX-HNTs) significantly inhibited osteosarcoma cells (K7M2WT) 
proliferation at low concentration (50 µg/ml). Simultaneously, other types of cells were 
not hardly harmed at this condition. Most importantly, the bHNT did not show an 
aggressive attack to normal cells (MC3T3). In order to verify that the cell growth 
inhibition was caused by the loading drugs instead of the drug carriers (bHNT), we 
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analyzed the cell viability by co-culturing cells with bHNT without drugs (FA/FITC-
HNTs). The results showed that none of osteosarcoma or pre-osteoblast cultures were 
affected by the bHNT (Figure 3-11 C). This finding is consistent to the previous study of 
CT26WT, that low dosage of bHNT did not present cytotoxicity (Figure 3-4). 
 
 
Figure 3-11: A. Schematic representation of osteosarcoma cells (K7M2WT), murine 
colon carcinoma cells (CT26WT) and preosteoblast cells (MC3T3)  co-culturing with 
bHNT. B. Cell proliferation of above 3 types of cells after co-cultured with 50 µg/ml 
drug loaded bHNT for 24 hours. C. Cell proliferation of above 3 types of cells after co-
cultured with 50 µg/ml bHNT for 24 hours 
3.4 Discussion 
Targeted drug delivery aims to decrease the side effects of highly toxic drugs 
through the delivery specifically to the target sites without harming surrounding healthy 
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cells. The use of targeted drug delivery systems in chemotherapy has attracted a great 
deal of research interest. Various biomaterials have been used in developing drug 
delivery systems with targeting capabilities. Liposomes are small self-assembled 
spherical vesicles consisting of bilayer phospholipids. Due to their intrinsic 
biocompatibility, size, hydrophobic and hydrophilic character, and ease of fabrication, 
liposomes are a promising system for drug delivery 128,  and several liposomal-based 
drugs have been approved 129. However, liposomes are often unstable 130. In order to 
improve their stability, excessive modification processes are often required 131. which 
increases labor, material, and cost. Nanoparticles generated with biodegradable polymers 
belong to another group of potential drug delivery systems. In the process of 
nanoparticles production, the size, structure, physicochemical properties, drug loading 
and releasing mechanism can be modified as needed. However, toxic chemicals are 
usually involved in the fabrication of nanoparticles. These are hazardous to the 
environment and to the body’s physiology 131. Furthermore, most nanoparticle fabrication 
procedures are suitable for laboratory-scale fabrication but often are not scalable for 
industrial production.  
Halloysite nanotubes are inexpensive, naturally formed eco-friendly nanoparticles 
with many desirable material properties 107. Their physical and chemical stability, 
biocompatibility, and modifiable surfaces enable HNTs to be a key component in drug 
delivery 109,110,132. Cationic therapeutic agents can be entrapped on the polyanionic 
surface of HNTs by chemisorption or encapsulated into their hollow lumens by 
vacuuming. Additional surface modification is often implemented to make 
multifunctional halloysite nanotubes 99,109. HNTs can be functionalized with -NH2 group 
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using aminopropyltriethoxysilane (APTES) and then conjugated with folic acid. In a 
study of Guo et al., (2012) FA and magnetite nanoparticles (Fe3O4) were successfully 
grafted onto the HNT surface. The coated Fe3O4@HNTs exhibited a pH-sensitive drug 
release behavior under the electrostatic interaction between the cationic drug and the 
HNTs. 13 Wu et. al., (2018) also functionalized HNT with APTES and conjugated its 
surface with PEG and folic acid, and then drugs were loaded by physical adsorption. The 
final product (DOX@HNTs-PEG-FA) effectively inhibited tumor growth with reduced 
side effects observed in the heart, spleen, lung, and kidney 133.   
However, one limitation of HNTs-PEG-FA is their drug loading efficiency is very 
low, only 3% for doxorubicin 133. In contrast, our FA/FITC-HNTs system had a much 
higher drug loading efficiency, with methotrexate-loading over 30%. Another limitation 
is that the HNTs-PEG-FA drug delivery systems can target tumor cell but cannot avoid 
potentially impacting other healthy tissues. In contrast, FA/FITC/MTX-HNTs only 
inhibited the growth of osteosarcoma (K7M2WT) without inhibiting the growth of 
MC3T3-E1 and CT26WT cells. This result may be due to the use of different drugs, 
different methods for drug loading, or the different types of cells studied.  
The intracellular pathway of HNTs was previously studied by Liu et al 126. They 
also modified HNTs with APTES and labeled HNTs by FITC. Cells were treated by four 
different inhibitors respectively and cocultured with functionalized HNTs. They found 
both clathrin- and caveolae- dependent endocytosis take part in cells internalization of 
HNTs 126. Also, Liu’s group found that HNTs were transported by microtubules and actin 
microfilaments with involvement by the Golgi apparatus and lysosome 126. Our finding is 
consistent with their study, but we observed that caveolae-mediated endocytosis took the 
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major role and clathrin-mediated endocytosis only worked as a supplementary 
mechanism in HNT-DAS-FITC/FA endocytosis. This difference between our results and 
Liu’s results may be due to different surface modification strategies.  
A significant body of research has been done to in developing targeted drug 
delivery using HNTs 7,13,126,133,134. Previously our lab has conducted studies on drug 
loading and release of MTX from HNTs from a polymer, nylon-6 11.This study directly 
targeted delivery of MTX specifically to osteosarcoma cells and inhibited osteosarcoma 
cell growth without inhibiting proliferation in other cells types. We modified HNTs with 
DAS instead of the traditional modification of HNTs with APTES, which has several 
advantages 135.  The system developed by the Hu et al., (2017) uses FA-conjugated to 
PEG deposited on the HNT surface. Our system prevents the dissociation of FA from the 
surface by covalently linking it to DAS. HNT-DAS-FA/FITC has both an imaging and 
targeting agent covalently attached to the surface of the HNTs. By incorporating an 
imaging moiety in the system, the efficacy of the treatment option can be monitored. 
Additionally, the HNT-DAS-FITC/FA is modular, allowing the system to be applied to a 
range of targets.  
Our HNT-based drug delivery system has the potential to provide localized and 
targeted therapy for the treatment of osteosarcoma that limits or reduces potential 
negative side effects, reducing patient costs and length of treatment and improving 
quality of life. The HNT interior can be loaded with a variety of anti-cancer drugs (or 
other chemotherapeutics) that serve as a “death cargo” designed to kill cancer cells while 
providing feedback imaging data on drug efﬁcacy. The surface of the HNT can be 
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modiﬁed with copper, iron or silver nanoparticles and used in photothermal therapy by 
converting light to heat inside tumor cells.  
3.5 Conclusion 
In summary, DAS-functionalized HNTs have a high drug loading efficiency 
(34.74% ± 3.5%). They are taken up by cells primarily though caveolae-mediated 
endocytosis and assisted by clathrin-mediated endocytosis. As far as authors are aware, 
we are the first to analyze the effects of HNT particle size on cell viability and have 
demonstrated smaller HNT size leads to increased cytotoxicity leading to cellular 
apoptosis. Compared to the typical size of HNTs, HNTs reduced in overall length were 
taken up by cells in greater amounts leading to cellular apoptosis. After conjugation with 
FA, MTX was effectively delivered to osteosarcoma. Most importantly, this is a specific 
target drug delivery; only osteosarcomas were affected, while the cell growth of murine 
colon carcinoma cells and pre-osteoblasts were not inhibited. All these results suggest 
that the DAS functionalized FA/FITC/MTX-HNTs may have a potential in targeting 
therapy for the treatment of osteosarcoma.  
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CHAPTER 4 
ZINC LOADED HALLOYSITE COPPERATING WITH 
POLYLACTIC ACID FOR BONE REGENERATION  
4.1 Introduction 
Three-dimensional (3D) printing has been a popular technology used in bone 
tissue engineering due to its ability to print out porous scaffold with designed structure 
with desired porosity and pore size. 3D printing associates with computer-aided design 
(CAD) to generate a 3-dimentional solid object from a digital data file, which can be used 
to create highly detailed and patient-specific models for surgical planning. Biomaterials 
commonly used in 3D printing are polymers (synthetic and natural), ceramics, and 
metals. Each biomaterial has specific physicochemical properties, processing methods, 
and cell-material interactions 136. Polymer materials are more popular than others due to 
their tunable properties, low melting point, low weight and processing flexibility. 
Although polymers can be printed for complicated geometric structure, lack of 
mechanical strength and functionality limited their wide applications; therefore, 
development of composite materials that are compatible with available printers and that 
provide desirable mechanical and functional properties has attracted tremendous 
attention.  
Polylactic acid (PLA) is a popular biomaterial used for 3D printing. It is a 
thermoplastic polymer that is derived from fermented corn starch, cassava starch or 
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sugarcane. It is an ecofriendly bioplastic as it is completely biodegradable and consists of 
renewable raw materials 137. PLA has two optical isomers, D and L. PLLA has a melting 
point of 175-178°C and a glass transition temperature of 60-65°C. This material exhibits 
high tensile strength, low elongation and high modulus, which enable it to be a good 
candidate for load-bearing applications, such as orthopedic fixation and sutures 137. PLLA 
can last more than 2 years in the body 137. PDLA is an amorphous polymer, which has a 
lower tensile strength, higher elongation and faster degradation time. Those features 
make it more attractive as a drug delivery system 137.  
Bone is a porous tissue, and its interconnected pores allow cell migration and 
proliferation, as well as vascularization. Scaffold properties such as adequate pore size, 
porosity, interconnectivity, and bioactivity have strong influence on bone engineering as 
well. In addition, the porous structure helps biomaterial to interlock native bone tissue, 
providing a greater mechanical stability at insert site 138. Porous bone scaffolds can be 
made by a variety of methods: salt leaching 139, chemical/gas foaming 140, freeze-drying 
141, and sintering 142. However, pore size, pore distribution, porosity, and pore 
interconnectivity cannot be precisely controlled in these approaches 143. Such scaffolds 
can be designed and fabricated using 3D printing. 
In order to optimize the integration between scaffolds and native tissue, 
osteogenic scaffold should mimic bone morphology, structure and functions. Bone 
consisted by 10% of bone cells and 90% of bone matrix 144145.  The main components of 
bone matrix are hydroxyapatite [Ca10(PO4)6(OH)2] (50-70%) and organic matrix (20-
40%) 146. Collagen type I takes 95% of total organic matrix 147. Trabecular bones have a 
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porous structure with 50-90% porosity and pore size of 1 mm in diameter 148, while 
cortical bones has a solid structure with a lower porosity of 3-12% 149.  
From a previous study, porosity did not affect cell attachment, but high porosity 
promotes cell proliferation, due do its bigger pore space and facilitation of oxygen and 
nutrients transportation 150. In contrast, lower porosity stimulates alkaline phosphatase 
activity and more osteocalcin secretion 150. Pore size also plays an important role in 
extracellular matrix production and the progression of osteogenesis. Small pores (90-
120µm) generate hypoxic conditions and induce osteochondral ossification, while large 
pores (350µm) allow high oxygenation and vascularization which lead to direct 
osteogenesis 151. Smaller pores (<100µm) enhance cell proliferation 152153. while larger 
pores (>100 µm) are good for cell migration. Based on the study of Hublber et al., the 
minimum requirement of pore size is 100 µm for cell growth and migration 154, however, 
pore sizes >300 µm are recommended due to enhanced bone formation and 
vascularization 155156.  
The pore size and porosity also play an important role in implants degradation. A 
proper balance between bone regeneration and degradation of biomaterial is desired 157. 
However, the mechanical properties of implants are decreasing with the degradation of 
biomaterials. Therefore, various hybrid materials have been explored to build 3D 
structure to archive desirable properties. For instance, the reinforcement for polymer 
usually archived by addiction of particle 158, nanocomposites 159 and fibers 160. In this 
study we used halloysite nanotubes (HNTs) to improve PLA mechanical properties. 
HNTs are naturally formed nanotubes with a hollow tubular lumen. Their inner diameters 
are 10-30nm and their outer diameters are 50-70nm. Their lengths typically vary in the 
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range of 0.5-1.5 µm 2. HNTs have been incorporated with variety of polymers, such as 
poly(butylene succinate) 161, rubber 162, epoxy 163, poly(methyl-methacrylate) 10, alginate 
51 and chitosan 49. HNTs improved their mechanical strength, increased surface toughness 
and thermal stability. Therefore, we also employed HNTs as our filler to reinforce PLA 
3D scaffold.  
Besides pore size, geometry, porosity and mechanical strength, surface properties 
such as surface charge, topography, and chemistry are also critical parameters to affect 
the success of the implanted scaffolds. At an early stage, bone ingrowth generated from 
the periphery of scaffolds and presents a negative gradient in mineralization toward the 
inner parts 164. Thus cell adhesion is the premier stage for bone regeneration.  Many 
studies have proved that surface charge 165166, roughness167, surface adsorbed proteins, 
and hydrophilicity/hydrophobicity 168 greatly influence on the cell attachment and direct 
cell behaviors. PLLA is a versatile, biodegradable, and FDA approved biomaterial 137, but 
an extra process is required to neutralize its hydrophobicity and low surface energy to 
improve cell adhesion.  
In this study, PLA was blended with metal-doped halloysite nanotubes (HNTs) in 
order to improve the mechanical properties of 3D printed scaffold, simultaneously, 
halloysite nanotubes have been reported to enhance osteogenic differentiation 169. As 
previously mentioned large pores and high porosity result in direct osteogenesis 151,155,156. 
Therefore, we printed the scaffold for 60% porosity with an average of 600 µm pore size. 
Scaffold mechanical properties and cell-material interactions were studied. The aim of 
this study is to generate a 3D printed scaffold to support bone regeneration and prevent 
bacterial contamination, which may be potentially used for bone defect therapy in a 
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clinic. Therefore, we also coated the 3D printed scaffold with antibody to prevent 
surgical contamination. The antibacterial ability of drug coated scaffold was assessed 
after 3 weeks stock time.  
4.2 Materials and Methods 
4.2.1 Material Preparation 
Four compositions were tested in this study: PLA, PLA+HNTs, PLA+HNTs/Zn, 
and PLA+HNTs/Zn+Gentamicin. In order to print them by 3D printer, all the above 
materials were made into filaments. PLA were extruded by Noztek at 175°C and resulted 
in the filaments with diameter of 1.75±0.05mm. In order to archive a uniform distribution 
of HNTs in PLA, 10 µl of silicon oil were added into 20g PLA and vortexed for 10 
minutes, then 1.2g of HNTs were added and continually vortexed for another 10 minutes. 
The mixture of PLA+HNTs were poured into Noztek and extruded at 170 °C. Filaments 
of PLA+HNTs/Zn made in the same way as PLA+HNTs, the difference is HNTs loaded 
with Zn, the Zn loading percentage is 30% w/w. The mixture of PLA+HNTs/Zn was 
extruded at 165 °C. Group of PLA+HNTs/Zn+Gentamicin were fabricated as dipping the 
3D printed PLA+HNTs/Zn discs into 100mg/ml gentamicin solution for 24 hours.  
4.2.2 Zinc Loaded into HNTs 
Zinc nanoparticles (Zn nps) were deposited on HNTs by thermal decomposition of 
the metal acetate, as depicted in Figure 4-1. Zinc oxide (ZnO) and excess of acetic acid 
was reacted using a magnetic stirrer at 50°C. Acetic acid was replenished in the system 
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over time for 12h, and the mixture was boiled. The zinc acetate (Zn(OAc)2) obtained was 
filtered using Whatman NO.1 filter paper170.  
20g of (Zn(OAc)2) were mixed with 10g of HNTs in 50 ml water and 
magnetically stirred for 12h. The product was decanted and separated using 
centrifugation and heated at 350°C for 2h which led to thermal decomposition of the 
metal acetate attached to the HNTs to ZnO-HNTs171. 
 
Figure 4-1: Facile synthesis and characterization of ZnO nanoparticles grown on 
halloysite nanotubes for enhanced photocatalytic properties. 
4.2.3 3D Printing 
The above produced filaments were 3D printed into desired structure by ENDER 
3 printer at 225°C. The discs were designed to be 6´6´2 mm with a pore size with 
0.6mm (Figure 4-2). The diameter of inside lattice girders is 0.6mm.  
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Figure 4-2: The CAD graph of 3D printing structure. 
4.2.4 Compressive Test 
Compression testing was applied by CellScale Unit. 3D printed discs were 
compressed at a speed of 10 mm/min with a 200 N load cell. The strain and stress prolife 
were collected. At least 3 tests were performed for each composition.  
4.2.5 Morphology and Surface Characterization  
The morphology of 3D printed scaffolds was observed by scanning electron 
microscope (SEM) and laser confocal microscope. The surface coatings were confirmed 
by EDS and FTIR. The hydrophilicity change with coating was determined with contact 
angle measurement.  
4.2.6 Porosity 
The open porosity of 3D printed scaffold was calculated though liquid 
displacement. One 3D scaffold was immerged into 1.0 ml (V1) of DI water, then a series 
of vortexing and sonication were applied to force the liquid get into the pores of the 
scaffold. The total volume of scaffold and DI water was measured (V2), after the water 
was removed, the scaffold and the remain volume of DI water was measured (V3). The 
final porosity of the scaffold was calculated as below:  
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 porosity = 𝑉1 − 𝑉3𝑉2 − 𝑉3  Equation 4-1 
 
4.2.7 Cell Culture 
Pre-osteoblast (MC3T3-E1) cells were selected to analyze cell differentiation 
when they were cultured in the 3D printed scaffold. MC-3T3 E1 (ATCC) were cultured 
in alpha modification of Eagle’s medium (α-MEM, Hyclone) with 10% fetal bovine 
serum (FBS) and 1% Pen/Strep antibiotic (Life Technologies). Cells were cultured in a 
humidified incubator at 37 °C and 5% CO2 level.  
4.2.8 Surface Treatment of 3D Printed Scaffold for Cell Culture 
Three strategies were used to improve scaffold surface hydrophilicity: 1) 3D 
printed scaffolds were immersed into the Fetal Bovine Serum (FBS) for 24 hours, which 
labeled as FBS in below. 2) 3D printed scaffolds were treated as Strategy 1 then 
immerged into 10 N NaOH for 30 minutes and washed by DI water, which were labled as 
FBS+NaOH. 3) After 3D printed scaffolds were treated as in Strategy 2, they were 
incubated in FBS again for 24 hours, which are labeled as FBS+NaOH+FBS.  
Pre-treated 3D printed scaffold was put into 48 wells plate. Each well had one 
disc and was seeded by MC3T3 cells at 1´105/well. Cells were cultured in a humidified 
incubator at 37 °C and 5% CO2. Cell behaviors were evaluated at Days 7, 14 and 21.  
4.2.9 Cell Attachment Stain 
Cells were incubated with scaffold for 24 hours and co-cultured with Hoechst 
33342 for 30 minutes at 37 °C and 5% CO2. Then cells were fixed by 4% 
paraformaldehyde for 15 minutes and stained by actin-stain 488 phalloidin according to 
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the manufacture’s protocols. Cell nucleus and actin filaments were observed by 
fluorescent microscope under DAPI and FITC filter, respectively. 
4.2.10  Cell Proliferation 
Cell proliferation was tested by MTS reagent. Cell were incubated as above, and 
at Day 14 and 21, 40 µl of MTS was added into cell culture plates and incubated for 2 
hours at 37 °C in darkness. 200 µl of supernatant of each sample were transferred to 96-
well plates and read absorbance values at 490nm by microplate reader. Cells cultured 
without scaffold used as the control.  
4.2.11 Cell Differentiation 
Osteocalcin Quantikine ELISA kit (R&D system) was employed to measure 
osteocalcin (OC) as a marker for osteogenic differentiation. Three scaffolds were 
assessed for each condition. Cell culture supernatant were collected for ELISA analysis. 
ELISA plates were processed according to manufacturer’s protocols. A standard curve 
was generated to determine osteocalcin concentration. Controls scaffolds were incubated 
without cells set as negative control and cells cultured in regular 2D condition were used 
as positive controls.  
4.2.12 Mineralization-Alizarin Red Staining  
Matrix mineralization will be assessed by Alizarin Red S (ARS) staining. Cells on 
scaffolds were ﬁxed with 4% paraformaldehyde for 15 minutes at room temperature, then 
stained with 2% ARS for 30 minutes. The samples were washed by DI water 4 times and 
observed under a microscope. Digital images of stained scaffolds were acquired using a 
brightfield microscope. Cells cultured in regular 2D condition were set as controls. 
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For quantification, 3D printed discs were transferred to 1.5 ml microcentrifuge 
tubes and immersed in 200 µl of 10% acetic acid, after which they were incubated for 30 
minutes at a horizontal shaker at speed of 500 rpm/min. All the microcentrifuge tubes 
were vortexed for 30 seconds, and after 10 minutes incubation at 85°C, they were cooled 
down in ice for 5 minutes. Tubes were centrifuged at 20,000xg for 15 minutes, 200 µL of 
the supernatant were transferred to a new 1.5 ml microcentrifuge tube and neutralized the 
pH with ~75 µL 10% Ammonium hydroxide to make pH in the range of 4.1-4.5. A 
standard curve was generated to determine the Alizarin Red Staining. 50 µL of standard 
and sample were added into a 96-well plate and read at OD405.  
4.2.13 Picrosirius Red Staining 
Picrosirius Red is a specific collagen fiber stain that is capable of detecting thin 
fibers. Media was removed from the cell culture plates and washed with DPBS before 
being fixed by 4% paraformaldehyde. These fixed cells were stained with Picrosirius Red 
for quantifying the amount of collagen secreted. Picrosirius stain was added into each 
well and removed after an hour incubation at room temperature. The cells were rinsed 
with 0.5% acetic acid solution twice and absolute alcohol twice. Digital images of stained 
scaffolds were acquired using a brightfield microscope. Cells cultured in regular 2D 
condition were used as controls.  
4.2.14 Antibacterial Efficiency 
Staphylococcus aureus (S.aureus) gram positive bacteria maintained in tryptic soy 
agar was used in this study. For testing, the bacterial strain was cultured in nutrient broth 
and plated on Muller-Hinton agar plates at 37°C overnight after which a single colony 
was picked up using a sterile toothpick and suspended in saline solution and diluted to 0.5 
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McFarland standard (1.5 x 108 CFU/ml). The antibacterial potential was evaluated 
against S. aureus using a microdilution broth assay. 3D scaffolds were immersed in 24 
well plates containing 1ml/well Muller Hinton broth with 20µL of 0.5 McFarland 
standard S. aureus, the plates were put on a shaker at 37°C. The absorbance of 100µL 
solution at 630nm was recorded after 12 hours incubation.  
4.2.15 Statistical Analysis 
One-way ANOVA or Student T-test was used for statistical analysis. Data were 
expressed as mean ± standard error. A p-value less than 0.05 was considered statistically 
significant.  
4.3 Results 
4.3.1 Morphology of 3D Printed Scaffold and Surface Characteristics 
All the filaments were printed into pre-designed structure with a pore size of 600 
µm*600 µm and a layer height of 600 µm (Figure 4-2). However, due to the limitation of 
the 3D printer, the resolution changed slightly. The precisely pore size was determined by 
laser confocal microscope (Figure 4-3). Based on measurement of 60 pores from 20 3D 
printed scaffolds the final pore size is 584.16±95.28µm in vertical distance and 
620.39±93.03µm in horizontal distance and with a porosity of 60.22±9.5%. 
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Figure 4-3: A. optical & laser combined picture of 3D printed disc. B. Laser confocal 
image of 3D printed disc. C. Horizontal section of selected pore, the horizontal 
distance was measured (584.16±95.28 µm, n=60). D. Vertical section of selected 
pore, the vertical distance was measured (620.39±93.03µm, n=60). E. Vertical section 
of selected pore, the layer thickness was measured (423.15±82.7µm, n=60). 
In order to improve cell adhesion, the hydrophobic surface of scaffolds was 
treated by FBS, FBS+NaOH and FBS+NaOH+FBS respectively. The deposition of each 
treatments was determined by EDS and their affection on surface was observed by SEM 
(Figure 4-4). At least 3 samples were detected for each treatment. Fetal bovine serum is 
the most commonly used serum to support cell growth invtro; it contains a variety of 
proteins and inorganic ions, such as sodium (Na), chlorine (Cl), and nitrogen (N). In 
order to confirm the deposition of FBS and NaOH, we detected them on the surface of 
the 3D printed scaffold. Their distribution on the surface is presented in Figure 4-4. 
Carbon (C) and oxygen (O) were distributed all over the scaffold, as they are the main 
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components of PLA. Na, Cl, and N can hardly be detected on the surface of naked PLA, 
while their deposition on other three groups varies due to different coating strategies. In 
order to accurately assessment of the surface modification efficiency for each strategy, 
we compared their deposition amount of Na (Figure 4-5), because both FBS and NaOH 
have Na. In our hypothesis, the deposition of Na would increase with each treatment. 
However, compared to the group modified with FBS along (1.65±0.3%, n=3), the 
addition treatment of NaOH (FBS+NaOH) decreased, rather than instead, the Na 
deposition it decreased (1.39±0.2%, n=3).The surface modified by FBS+NaOH+FBS has 
the highest accumulation of Na (2.45±0.15%, n=3), indicating that even though Na+ from 
NaOH did not deposit on the surface, its remains attracted more deposition of third layer 
of FBS. 
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Figure 4-4: The SEM images and EDS element analysis for 3D printed scaffold. The 
first picture of each group is the SEM images. Then the EDS graph for each element 
distribution. The distribution of C and O presented the similar pattern as the scaffold, 
due to they are the main elements consist PLA. In the EDS pictures of Na, Cl, and N, 
there are only few dots are presented in the group of PLA without coating and 
PLA+FBS+NaOH. In contrast, those elements presented a scaffold pattern in the 
group PLA+FBS and PLA+FBS+NaOH+FBS. 
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Figure 4-5: Deposition of Na for three modifications. (error bar with standard 
deviation, n=3, p<0.05). 
 
Surface modification aims to increase the hydrophilicity of scaffold, which can be 
detected by contact angle. In our hypothesis, the contact angle would keep decreasing as 
the hydrophilicity would be improved with each treatment. However, the changes of 
contact angle showed the similar change trendline as the Na deposition. The scaffold 
hydrophilicity increased after FBS treatment, but decreased with the treatment of 
FBS+NaOH, and increased again with the treatment of FBS+NaOH+FBS (Figure 4-6). 
One interesting phenomenon happened in the test of FBS+NaOH+FBS group, when 
water was dropped on the scaffold surface, it spread on the disc surface so fast. Because 
the surface turned to be highly hydrophilic. 
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Figure 4-6: Contact angle of different surface modifications. The average contact 
angle for PLA without coating is 66.4°±9.8° (left) and 61.7°±7.2° (right); for PLA 
coated with FBS is 24.4°±5.2° (left) and 26.2°±4.1° (right); for PLA coated with 
FBS+NaOH is 82.5°±9.8° (left) and 82.4°±10.4° (right); and for PLA coated with 
FBS+NaOH+FBS, no data could be recorded due to the highly hydrophilicity. 
4.3.2 Compressive Strength 
In order to improve the mechanical properties of 3D scaffold, we added HNTs 
into PLA. Several studies have reported HNTs were able to improve biomaterials’ 
mechanical properties 49,163,169. Therefore, we expected the addition of HNTs and zinc 
loaded HNTs to increase PLA compressive strength. However, due to the limitation of 
the instrument, the maximum force it can provide is 200N, and at this force, none of the 
scaffolds broke. Compressive modulus was calculated from stress and strain (Figure 
4-7). ANOVA analysis showed no significant difference among the three groups. 
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Figure 4-7: Stress vs. Strain profile and the compressive modulus of PLA, PLA+H, 
and PLA+H+Zn. The compressive modulus: PLA=0.28±0.01 MPa, 
PLA+H=0.27±0.02 Mpa, PLA+H+Zn=0.30±0.02 Mpa. (error bar with standard 
deviation, n=5).  
4.3.3 Cell Adhesion 
Three modification strategies exhibited different surface characters. Their 
influence on cell adhesion was studied by incubating cells with PLA, PLA+FBS, 
PLA+FBS+NaOH, PLA+FBS+NaOH+FBS for 24 hours and staining the cell nucleus 
and actin filaments. No cells detected on the uncoated surface of PLA, so we did not 
include a picture of this group. In contrast, all three coating strategies attracted cell 
adhesion, as shown in Figure 4-8. In addition, cell growth follows the scaffold direction. 
By comparing the cell nucleus number (DAPI) and actin fiber (FTIC) exhibition, it can 
be easily found PLA+FBS+NaOH+FBS has the best performance, while 
PLA+FBS+NaOH has the least cell adhesion. This finding is consistent to our previous 
surface character studies. Therefore, we coated all of our 3D scaffolds with 
FBS+NaOH+FBS for further cell behavior studies.  
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4.3.4 Cell Proliferation 
Cell proliferation was assessed after 7, 14, and 21 days incubation (Figure 4-9). 
In first week (D7), cell proliferation on 3D scaffold is not as good as conventional 2D 
cell culture, except scaffold composed by PLA. As incubation time increased, cell 
proliferation ability increased. After three weeks (D21) incubation, 2D and 3D cell 
cultures were significantly different. This is because 3D structure enables cell migration 
to the extra vertical plane, compared to 2D, the 3D structure has more adhesion surface. 
In order to decrease the risk of contamination, we coated the 3D printed scaffold with an 
antibiotic, gentamicin. Gentamicin inhibited cell growth in first 2 weeks, but in the third 
 
Figure 4-8: Cell adhesion on PLA with three coating strategies. First column is the bright 
phase. Second column is fluorescent pictures under DAPI filter, which represents cell 
nucleus. Third column is the fluorescent pictures under FTIC filter, which represents the 
actin fibers 
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week, the control group and gentamicin coated ones (PLA+H+ZN+G) are not 
significantly different.  
 
Figure 4-9: Cell proliferation ability when culture on conventional 2D surface 
(control) and 3D cultures that composed by PLA, PLA blended with HNTs (PLA+H), 
HNTs loaded with zince and blended with PLA (PLA+H+ZN) and scaffold made by 
PLA+H+ZN coated by gentamicin (PLA+H+ZN+G).  
4.3.5 Mineralization 
The potential application of this 3D printed scaffold is to regenerate bone 
formation. Thus, we studied the osteogenesis by assessing cell mineralization, collagen 
synthesis and protein secretion.  
Calcium deposition is an indication of bone formation, which can be identified by 
Alizarin Red S staining. The Alizarin Red S-calcium complex results in the chelation 
between calcium and Alizarin Red S stain and presents red color under a microscope at 
bright field. As shown in Figure 4-10, there is little calcium deposition in 2D cell culture 
condition (control), while calcium deposition appears in 3D culture structure as early as 7 
days incubation (Day 7). Calcium deposition increased with incubation time. 
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Figure 4-10: Alizarin Red S Staining of cells after 7, 14, and 21 days incubation. 
Each column represents cell culture with each group of scaffolds for 3 weeks. Arrows 
point to calcium deposition.  
4.3.6 Collagen Synthesis 
Even though the mechanical property enhancement is not significant with the 
addition of HNTs, its influence on type I collagen formation is distinct. Picro-sirius Red 
could stain type III collagen to be red and type I collagen to be yellow. Type I collagen is 
the major component of bone tissue extra cellular matrix (ECM), which is mainly 
synthesized by osteoblasts. The synthesis of type I collagen is one of the markers that 
indicates osteogenic differentiation. 
In this study, when cells were cultured in 2D condition (control), a few collagens 
were synthesized in 7 days, and over incubation time more collagens were formed. Based 
on to the appearance of colors, most collagens produced in the 2D condition are type III, 
and only a few of type I collagens occurs after 21 days incubation. Comparing to 2D cell 
culture, more collagens were formed in 3D scaffolds (Figure 4-11and Figure 4-12). In 
addition, the appearance of type I collagen in 3D scaffold arose in 14 days with the 
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scaffolds that contained HNTs. At that time, type I collagen only appears at the bottom 
layer of the scaffold (Figure 4-12), after one more week incubation (Day 21), type I 
collagen also formed at the inner space (Figure 4-11). 
 
Figure 4-11: Picro-sirius Red Stain for inter space of 3D scaffolds. Arrows point to 
type I collagen.  
 
Figure 4-12: Picro-sirius Red Stain for bottom layer of 3D scaffolds. Arrows point to 
type I collagen.  
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4.3.7 Osteocalcin 
Osteocalcin is another protein that is widely found in bone tissue and that can be 
secreted only by osteoblasts. Therefore, it is another indication for osteogenic 
differentiation. Since the mineralization and type I collagen widely happened after 14 
days incubation, we quantified the osteocalcin at day 14 (D14) and day 21 (D21). Figure 
4-13 shows no significant difference among all groups at day 14. After one more week 
incubation, the increment of osteocalcin secretion of 3D scaffold with PLA+H, 
PLA+H+Zn is relatively higher than in 2D culture (control). In addition, cells grown on 
scaffold PLA+H+Zn+G secreted much more osteocalcin than any other groups.  
 
Figure 4-13: Osteocalcin concentration secreted by cell after 14 days (D14) and 21 
days (D21) incubation. (error bar with standard deviation, n=3, p<0.05). 
4.3.8 Antibacterial Efficiency 
In order to reduce the risk of contamination in clinic application, we coated the 
3D scaffold with gentamicin and co-cultured with S. aureus for 12 hours. Bacterial 
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growth was measured by microplate reader at 630nm (Figure 4-14). In our hypothesis, 
zinc-included 3D scaffold may also exhibit antibacterial ability. However, maybe due to 
the deep submergence of zinc, the group of PLA+H+Zn did not inhibit bacterial growth. 
In contrast, the gentamicin-coated 3D scaffold prevented bacterial growth, as expected. 
 
Figure 4-14: Bacterial growth inhibition efficiency. Broth without any sample and 
bacterial set as negative control (Broth). S.aureus culture in broth set as positive 
control (S.aureus). Same amount of S.aureus suspension was co-cultured with 
scaffold composed by PLA, HNTs included PLA (PLA+H), Zn loaded PLA 
(PLA+H+Zn), and gentamicin coated PLA (PLA+H+Zn+G). (error bar with standard 
deviation, n=3, p<0.05). 
4.4 Conclusion and Discussion 
In summary, surface modification of FBS+NaOH+FBS successfully improved 
PLA hydrophilicity and provided a friendly and attractive surface for cell growth. In this 
study, we aim to stimulate pre-osteoblasts to differentiate to osteoblast in 3D 
environment by utilizing the osteogenesis properties of HNTs. Osteogenic cell culture 
medium was excluded in this study due to its strong stimulation in osteogenic 
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differentiation. After 3 weeks incubation, early bone formation was detected. Calcium 
deposition and type I collagen formation initiated from the bottom layer of 3D scaffold 
and gradually happened in the inner space. This phenomenon is consistent with another 
work of Jones et. al 164. 
In our hypothesis, the addition of HNTs could improve PLA mechanical 
properties and stimulate cell differentiation. However, mechanical property enhancement 
is not significant, in contrast, HNTs exhibited osteogenesis by promoting type I collagen 
formation in a short incubation time and stimulating the osteocalcin secretion. 
Even though the coating of gentamicin affected cell growth in early stage, cells 
recovered from its affection and exhibited a strong osteogenesis in the third week. 
Furthermore, after 3 weeks storage, it still efficiently restricted bacterial growth. 
In conclusion, 3D scaffold made by PAL+H+Zn+G composed dual effect in 
stimulating bone formation and preventing bacterial contamination. This bi-
functionalized scaffold has a great potential application in clinical bone defect treatment.  
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CHAPTER 5 
 
CONCLUSION AND FUTURE WORK 
 
5.1 Conclusions 
All three projects have been conducted to explore the application of halloysite 
nanotubes in medical devices for bone disease remediation and bone regeneration. 
The reinforcement properties of halloysite nanotubes for polymer material have 
been demonstrated in Chapter 2. As early as 1980’s, chitosan has been used as 
pharmaceutical material 172. The unique properties of chitosan, including its 
biocompatibility, biodegradation, gelation characteristics, and relative antimicrobial 
ability, have enabled its applications in pharmaceutical products, such as wound dressing 
173 and controlled drug release 174,175. However, it is difficult to control the mechanical 
properties of chitosan-derived hydrogels, which limits its application in tissue 
engineering. In this study, the addition of HNTs provided strong material support to 
chitosan hydrogel. Chitosan hydrogel film surface toughness, tensile strength, and outer 
and inner morphology were enhanced as well. In the study described in Chapter 2, we 
explored different combination ratios of chitosan and HNTs and found 2% w/w of HNTs 
provided the highest tensile strength. Because excessive addition of HNTs results in 
interfacial gaps, this weakens the composites’ toleration for force loading and limits how 
much HNTs can be added. 
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Halloysite nanotubes application in drug delivery has been reported in many 
studies 4,51,176. HNTs can significantly extend drug release time. When they are 
encapsulated by polymers, the drug release time can be extended longer, which was 
shown as Chapter 2, chitosan/HNTs provides sustained drug release for over 104 hours. 
Recently, development of drug delivery systems based on halloysite nanotubes 
has archived major advance through surface modification in order to increase drug 
loading efficiency 5,177 and target drug delivery to cancer tumors 115,133. In Chapter 3, 
HNTs were modified by DAS and conjugated with folic acid and fluorescein 
isothiocyanate. The final product of FA/FITC-HNTs had a 34.74% drug loading 
efficiency of methotrexate, which is much higher than normal treatment with a 10-20% 
drug loading efficiency 133,178. In addition, our biofunctionalized HNTs successfully 
target cancer cells without harm to normal cell. 
Even though, the addition of HNTs did not show a significant improvement in the 
mechanical property to 3D printed PLA scaffold as discussed in Chapter 4, HNTs showed 
an osteogenesis potential. In the presence of HNTs, pre-osteoblasts synthesized an early 
formation of type I collagen matrix and osteocalcin secretion. Gentamicin coating also 
did not significantly inhibit cell growth. Gentamicin-coated scaffold showed an increased 
and comparable cell proliferation ability with control groups by day 21. Unexpectedly, 
pre-osteoblast exhibited a strong osteogenic response in the presence of gentamicin. 
Therefore, gentamicin-coated PLA/HNTs scaffold could not only prevent bacterial 
contamination but also promote bone regeneration.  
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5.2 Future Work 
After we have confirmed the proper combination ratio of chitosan and HNTs, 
there are much room to explore its application in biomedical engineering. Chitosan/HNTs 
hydrogels can be produced in different structures, such as microspheres and films, or cast 
into designed molds. In addition, instead of antibodies, halloysite nanotubes can be 
loaded with other biological factors, such as transforming growth factor b1 (TGF-b1), 
bone morphogenic protein 2 (BMP-2), activin-A, epidermal growth factor (EGF), and 
hepatocyte growth factor (HGF) to exploring its potential in tissue engineering. 
HNTs modified with DAS-FA/FITC have a high drug loading efficiency of 
methotrexate, this may due to the similar chemical structure of folic acid and 
methotrexate. The drug loading efficiency for other anticancer drugs remains to be 
assessed. Their influence on healthy tissues and anticancer ability in vivo study is also 
waiting to be discovered. 
Many obstacles remain to be overcome in the application of metal-loaded HNTs 
in 3D printing. In the study of Chapter 4, halloysite loaded with zinc, which is known as 
osteoconductive agent, was studied. However, this property did not appear in our study. 
This may be due to the deep encapsulation of zinc as it was loaded into HNTs and coated 
by PLA. Future studies should focus on how to improve the release of metal particles 
from a 3D printed scaffold. 
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